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MECHANISMS AND CONSEQUENCES OF MYB GENE ACTIVATION IN
SALIVARY GLAND TUMORS
by
Candace Frerich
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Ph.D., Biomedical Sciences, University of New Mexico 2019

ABSTRACT
Salivary gland adenoid cystic carcinoma (ACC) is an aggressive tumor
with a tendency to infiltrate surrounding nerves and metastasize to distant sites.
The standard treatment often fails to control local tumor recurrence and distant
metastases and no approved targeted therapeutic options exist for these tumors.
The goal of our studies was to reveal the molecular mechanisms driving ACC
tumor development and novel drug targets to improve patient morbidity and
mortality.
We first analyzed clinical and RNA-sequencing (RNA-seq) data for 68
formalin-fixed paraffin-embedded (FFPE) ACC tumor samples and described
previously unappreciated molecular heterogeneity that predicts patient outcome.
The poor outcome subgroup had a gene expression signature that resembled
embryonic stem cells, suggesting these patients had high-grade dedifferentated
tumors. We also utilized these RNA-seq data to definitively show that the MYB
and MYBL1 genes are the oncogenic drivers in the vast majority of ACC tumors.
ACC tumors that expressed Myb oncogenes were distinct from those that did not,
iv

indicating that Myb driven tumorigenesis in ACC tumors results in a unique gene
expression pattern. From these analyses we identified and validated the first two
high-confidence Myb regulated genes in ACC tumors, the first step in unraveling
how Myb driven gene expression changes drive oncogenesis.
The MYB gene must be truncated to unleash its oncogenic potential, in
ACC tumors this typically occurs at the C-terminus via chromosomal
translocations. However we only observed gene truncation in half of the MYB
expressing ACC tumors, raising a new question: how is the oncogenic potential
of MYB unleashed in those tumors that appear to express the full-length gene?
We found that nearly all of the MYB expressing ACC tumors had an activated
alternative MYB gene promoter, which produces N-terminally truncated Myb
proteins. Thus, alternative promoter use may unleash the oncogenic potential of
the Myb protein in those ACC tumors that appeared to express the nononcogenic full-length protein. Further investigation revealed significant
differences in the gene expression signature elicited by N-terminally truncated
Myb isoforms and full-length Myb isoforms. Specifically, N-terminally truncated
Myb isoforms uniquely activated a pro-tumorigenic neural migration signaling
pathway. A pathway linked to increased perineural invasion, an ACC tumor
hallmark associated with poor prognoses. Indeed, we found stratification of ACC
tumors by expression of these genes identified a significantly poor outcome
subgroup.
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The clinical heterogeneity that makes ACC tumors so difficult to treat may
be predicted by molecular characterization, thus identifying high-risk patients who
are candidates for more aggressive care or personalized therapies. A previously
unidentified truncated Myb isoform stimulates perineural invasion, a significant
roadblock to curative treatment. These studies have many implications for future
studies of the mechanisms of Myb driven tumorigenesis, development of more
effective targeted therapeutics, and ultimately patient treatment.

vi
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CHAPTER 1- INTRODUCTION
1.1 The c-Myb transcription factor determines cell fate
1.1.1 Normal c-Myb balances proliferation and differentiation
The c-Myb transcription factor, encoded by the MYB gene, regulates the
expression of thousands of genes to coordinate proliferative and differentiated
cell states in multiple normal cell types (Mucenski et al. 1991; Malaterre et al.
2008; Matsumoto et al. 2016; Zorbas et al. 1999). Indeed, c-Myb expression is
linked to the differentiation state of the cell, where immature, highly proliferative
cells produce high amounts of c-Myb. But as proliferation slows and these cells
differentiate c-Myb expression coordinately decreases, until expression of c-Myb
is essentially zero in terminally differentiated cells (Figure 1.1A). Early studies
demonstrated c-Myb is essential for early haematopoiesis and MYB gene
knockout is lethal at embryonic day 15. Knockout animals lacked any of the
differentiated blood cell lineages, a catastrophic failure for life (Mucenski et al.
1991). Further studies revealed the dual nature of c-Myb in controlling cell fate;
perturbation of c-Myb function led to defects in both proliferation and
differentiation (Figure 1.1B). Specifically, MYB knockout cells failed to progress at
three different stages of T-cell differentiation (Bender et al. 2004) whereas
dominant negative inhibition of c-Myb in immature thymocytes also prevented
resumed proliferation (Pearson and Weston 2000). More recently, the role of cMyb in governing proliferation and differentiation has been expanded to include a
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Figure 1.1. The c-Myb transcription factor controls cell fate.
(A) The role of c-Myb in cell fate is best understood in haematopoiesis, where it
is necessary for both proliferation of immature progenitor cells and their
differentiation into specialized blood cells. c-Myb expression is high in
proliferating cells (indicated by the red wedge), and gradually decreases as the
cells differentiate, so that terminally differentiated cells do not express c-Myb at
all. (B) Disruption of c-Myb function via knock out or inhibition leads to defective
proliferation and differentiation.
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multitude of normal cell types including colon progenitors, neural progenitors, and
normal salivary gland(Mucenski et al. 1991; Malaterre et al. 2008; Matsumoto et
al. 2016). As in the hematopoietic system, c-Myb is expressed early in normal
salivary gland development but is silenced in fully differentiated cells. During
branching morphogenesis the ductal stalk elongates via rapid proliferation of
epithelial cells followed by differentiation as the bud at the end of the duct forms
(Matsumoto et al. 2016). Evidence suggests that c-Myb, in conjunction with Wnt
signaling, has an integral role in the maintenance and timing of proliferation
during this process (Matsumoto et al. 2016). Modulation of MYB expression in ex
vivo cultures of mouse salivary gland rudiments significantly altered duct
morphology, where MYB knockdown resulted in shorter ducts and an overabundance of terminal buds (Matsumoto et al. 2016) indicative of perturbed
proliferation. Hence, expression of c-Myb is necessary to maintain ductal cell
proliferation and delay bud cell differentiation. Thus, the normal role of the c-Myb
transcription factor is to coordinate the timing and balance of proliferation and
differentiation in multiple developing tissues.
1.1.2 c-Myb protein domains and transactivation
The c-Myb protein functions as a transcriptional regulator which is capable
of both activating and repressing transcription. The protein is composed of five
highly conserved domains which largely make up the DNA-binding and specificity
/regulatory regions (Figure 1.2A). The DNA-binding domain (DBD; amino acids
72-192) is perfectly conserved from humans to chickens and is strictly required
3

for DNA-binding. A single point mutation within this domain (at amino acid 167) is
capable of completely abolishing DNA-binding altogether, producing a dead
protein (Frampton et al. 1991). The DBD consists of two consecutive, imperfect
helix-turn-helix domains which form two globular structures that wedge
themselves into the flanking sides of the DNA major groove (Ogata et al. 1994).
Together these two domains, forming one DBD, recognize the degenerate hexanucleotide sequence motif of Cc/aGTTa/g, termed the Myb binding site. There
are more than 6 million potential Myb binding sites in the human genome, but
chromatin immunoprecipitation (ChIP) experiments demonstrated that c-Myb only
bind ~10 thousand of those (Quintana et al. 2011; Drier et al. 2016). Hinting that
c-Myb specificity is determined by factors beyond the DBD.
Together the DBD and transactivation domains (TAD; amino acids 260321; Figure 1.2A) are the minimum portion of the protein required for
transactivation in reporter assays (Frerich et al. 2018; Cuddihy et al. 1993;
Brayer et al. 2016). The c-Myb TAD is a powerful domain capable of directly
recruiting the basal transcriptional machinery and initiating transcription of bound
target genes (Figure 1.2B). In acute myeloid leukemia cells the TAD directly
recruits the TFIID general transcriptional co-activator complex, which in turn
nucleates the pre-initiation complex to initiate transcription (Y. Xu et al. 2018).
The c-Myb TAD is
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Figure 1.2. Conserved c-Myb protein domains serve diverse functions.
(A) The c-Myb protein is composed of several conserved domains. Together the
DBD and TAD are the minimal portion of the protein needed for transactivation.
The C-terminal regulatory domains (FAETL, TPTPF, EVES) are involved in
protein-to-protein interactions which contribute to the proteins transcriptional
specificity. (B) The c-Myb (cyan) TAD interacts with TAF12 or p300 co-factors
(pink) which directly recruit the general transcriptional machinery (transcription
initiation complex (TIC), green). c-Myb binding to DNA and interaction with
TAC12/p300 are likely stabilized by additional transcription factors and co-factors
(purple).
5

also able to directly interact with the general co-activator p300, which may
perform the same function of recruiting the basal transcriptional machinery to
initiate transcription (Sandberg et al. 2005). In both studies abolishing c-Myb
interaction with the general co-factor (either TFIID or p300) abolished up to 90%
of c-Myb transactivation.
The C-terminus of c-Myb is composed of multiple highly conserved
domains that contribute to the specificity and regulation of the protein (Figure
1.2A). The FAETL domain (amino acids 365-411) may stabilize Myb in a
functional conformation and is required for transformation in some assays (Fu
and Lipsick 1996). The TPTPF domain is highly conserved, yet has no known
function. Finally, the EVES domain is hypothesized to be involved in autoinhibitory intramolecular interactions, where it folds back to interact with the DBD,
thereby inactivating the protein (Dash, Orrico, and Ness 1996). It is clear that
removal of this portion of the protein leads dramatically increased transcriptional
activity (Fu and Lipsick 1996), qualitatively different transcriptional specificity (F.
Liu et al. 2006; Ness 2003), and the ability to transform cells (Dubendorff et al.
1992; Cuddihy et al. 1993).
1.2 Transcriptional regulation of the MYB gene
1.2.1 Upstream MYB promoter (TSS1)
As described above the correct timing and quantity of c-Myb is essential
for proper development. Extensive transcriptional regulation via multiple
mechanisms ensures correct MYB gene expression. Transcription of the MYB
6

gene typically begins at the promoter upstream of the first exon (TSS1; Figure
1.3). MYB TSS1 is within an annotated CpG island and is over 90% GC in some
regions (Dvorák et al. 1989). TSS1 lacks both a TATA box and a CAAT box,
instead it appears that transcription is initiated by Sp1 factor binding (Dvorák et
al. 1989). It is likely this promoter is regulated in a cell-type and cell-stage
specific manner by diverse signaling pathways, cell-type specific transcription
factors, chromatin structure, and DNA methylation. For instance, in T-cells IL-2
activation induced E2F and NF-κB binding of TSS1 to stimulate transcription,
which in turn stimulated proliferation and protected cells from apoptosis (Lauder,
Castellanos, and Weston 2001). Deletion of either E2F or NF-κB binding site
individually resulted in reduced MYB transcription and deletion of both completely
abolished MYB transcription in these cells (Lauder, Castellanos, and Weston
2001). Hence, MYB expression is maintained by highly coordinated interactions
between multiple tissue-specific transcription factors and signaling pathways.

7

Figure 1.3. Transcriptional regulation of the MYB gene.
Transcriptional regulation of the MYB gene is centered around the first ~5kb of
the gene including exon 1, intron 1, and exon 2. The upstream promoter (MYB
TSS1) is extremely GC-rich and lacks traditional TATA box or CAAT box,
transcription is likely initiated by SP1 binding. MYB TSS1 is activated by cell-type
specific transcription factors downstream of signaling pathways, for example, IL-2
signaling stimulates binding of E2F and NF-kβ. Within the first intron RNApolymerase encounters the attenuation site and stalls (yellow). Docking of cell
type specific cofactors, like NF-kβ in T-cells and estrogen receptor in breast
cancer, is necessary to relieve polymerase stalling and allow expression of the
gene. Just before the second exon is an AT-rich, rarely used alternative promoter.
This promoter has only been described in leukemia cells where binding of the
PBX2 transcription factor has a role in promoter selection.
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1.2.2 Transcriptional regulation via RNA-polymerase pausing
MYB expression is regulated in multiple cell-types by an RNA-polymerase
(RNA-pol) attenuation site within the first intron (hairpin structure, Figure 1.3)
(Yuan 2000; Pereira et al. 2015; H. Hugo et al. 2006). Transcription initiates at
TSS1 then proceeds through to the first intron. Approximately 1.7 kilobases (kb)
downstream of MYB TSS1 the newly transcribed RNA forms a hairpin structure
causing the RNA polymerase II to stall (Pereira et al. 2015). Polymerase stalling
is relieved by docking of regulatory proteins to the hairpin structure, allowing
transcriptional elongation to continue and produce full-length MYB transcripts
(Pereira et al. 2015). In colorectal cancer and hematopoietic cells elongation is
controlled by subunit specific binding of NF-kB to the RNA hairpin. Specifically,
p50-p50 homodimer binding blocked elongation. Whereas, p50-p65 heterodimer
binding recruited P-TEFb to phosphorylate Ser2 in the C-terminal domain of RNA
polymerase II which stimulated continued transcription of the remainder of the
MYB gene (Pereira et al. 2015; Suhasini and Pilz 1999; Perkel, Simon, and Rao
2002). A similar mechanism is employed in breast cancer cells, where estrogen
receptor binding the hairpin structure recruits P-TEFb and relieves transcriptional
attenuation (Drabsch et al. 2007). Thus, MYB transcription is tightly controlled at
the elongation stage by cell-type specific factors modulating ubiquitous
transcriptional machinery.
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1.2.3 Rare alternative MYB promoter (TSS2)
Genome-wide studies estimate that half the human genes have multiple
promoters, with an average of 4 promoters per gene (X. Wang et al. 2016). It is
increasingly clear that alternative promoter use is an important mechanism to
increase transcript and protein diversity (X. Wang et al. 2016). This is also the
case with the MYB gene, which has an alternative promoter within the first intron
directly upstream of exon 2 (MYB TSS2, Figure 1.3). TSS2 use has thus far only
been reported in leukemia cells lines (Dassé et al. 2012; Jacobs, Gorse, and
Westin 1994). Evidence from embryonic stem cells suggested GC-rich
promoters, like MYB TSS1, are active by default and must be actively silenced.
Whereas GC-poor promoters, like MYB TSS2, are inactive but can be selectively
activated by cell-type specific transcription factors (Mikkelsen et al. 2007).
Indeed, the two MYB gene promoters are activated differently in normal
hematopoietic progenitors and transformed myeloid cells (Dassé et al. 2012).
Where TSS1 was active in normal hematopoietic progenitors but MYB TSS2 was
active in transformed myeloid cells (Dassé et al. 2012). It appeared that cell-type
specific localization of the Pbx2 transcription factor to MYB TSS2 versus TSS1
was linked to TSS2 activation (Dassé et al. 2012). Thus MYB promoter selection
is likely achieved through differential recruitment of the basal transcriptional
machinery to different core-promoter types by cell-type specific factors (Gross et
al. 1998; Losick 1998; Mikkelsen et al. 2007).
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1.2.4 Distant enhancers regulate MYB gene expression
In addition to the extensive local gene structure described above, the
MYB gene can be regulated in trans by multiple distant enhancers. In primary
human erythroid progenitors and myeloid progenitor cells multiple enhancers
interacted with the 5’end of the MYB gene to form a dynamic chromatin hub that
encompassed the entire first ~5kb of the gene, including the first exon, first
intron, and second exon (Stadhouders et al. 2012; J. Zhang et al. 2016). As with
the other regulatory features of MYB these interactions appear to be cell-type
specific. In myeloid cells Hoxa9 and PU.1 were integral in maintaining enhancerpromoter interactions (J. Zhang et al. 2016), but in erythroid cells KLF1 and the
GATA1/TAL1/LBD1 bound and maintained the enhancer-promoter chromatin hub
(Stadhouders et al. 2012).

1.3 c-Myb is the founding member of the Myb transcription factor family
There are three members of the Myb transcription factor family: c-Myb (the
founding member), A-Myb, and B-Myb. (Henceforth, “Myb” generally refers to
Myb proteins as a whole or unnamed truncated isoforms, specific names will be
used when appropriate.) All three related transcription factors are expressed in
vertebrates and share a conserved DNA-binding domain (Figure 1.4). However,
the proteins have little conservation beyond the DBD and each transcription
factor has a unique function. Knock out of A-Myb, encoded by the MYBL1 gene,

11

Figure 1.4. The Myb family of transcription factors.
c-Myb, encoded by the MYB gene, is the founding member of the Myb
transcription factor family. Two other Myb transcription factors are expressed in
vertebrates, A-Myb and B-Myb, encoded by MYBL1 and MYBL2 respectively.
These homologs share a conserved DBD that was functionally identical in
domain swap experiments (Rushton and Ness 2001). The C-terminus of the
proteins are unique, and determine their transcriptional specificity. The oncogenic
v-Myb encoded by the AMV virus was the first discovered Myb protein. This is a
truncated, and mutated version of c-Myb, which causes a disease similar to
leukemia when expressed in chickens. (Henceforth, “Myb” generally refers to
Myb proteins as a whole or unnamed truncated isoforms, specific names will be
used when appropriate.)

12

results in male infertility (Toscani et al. 1997) and further studies identified it as a
master regulator of male meiosis (Bolcun-Filas et al. 2011). The B-Myb
transcription factor, encoded by the MYBL2 gene, plays an integral role in cell
cycle regulation and progression (Sadasivam, Duan, and DeCaprio 2012). Each
of these transcription factors regulates unique sets of genes and has different
roles in a cell, despite the conserved DBD (Rushton et al. 2003; Rushton and
Ness 2001). Domain swap experiments further illustrated that the DBD of these
three proteins were functionally interchangeable and the unique C-terminal
regulatory domains were responsible for maintaining the context-specific gene
activation of each transcription factor (Lei et al. 2004; Rushton et al. 2003).
In addition to the vertebrate Myb genes, there are multiple examples of
viral Myb homologs, which are all oncogenic. For example, the Avian
Myeloblastosis Virus (AMV) encodes the v-Myb protein (Figure 1.4). v-Myb is a
truncated, mutated, and oncogenic version of c-Myb that causes myeloblastosis,
a disease similar to leukemia, in infected chickens. As illustrated in Figure 1.4 vMyb is doubly truncated at both the N-terminus and C-terminus, only encoding
amino acids 72-442 of the full-length c-Myb protein. The activities of vertebrate
Myb proteins and truncated oncogenic v-Myb provided the first clues to Myb
transcription factor specificity, discussed in detail later.

13

1.4 How normal Myb transcription factors become oncoproteins
1.4.1 Normal full-length c-Myb does not transform cells
Early studies demonstrated that v-Myb was able to transform cells yet fulllength c-Myb had little to no transforming ability (Furuta et al. 1993; Grässer,
Graf, and Lipsick 1991). The oncogenic and transforming ability of the normal
vertebrate c-Myb transcription factor must be unleashed by truncation to either
one or both termini of the protein (Fu and Lipsick 1996; Hu et al. 1991; Ramsay,
Ishii, and Gonda 1991; Grässer, Graf, and Lipsick 1991).
1.4.2 N-terminal truncation
The highly conserved N-terminus of c-Myb is constitutively phosphorylated
at S11/S12 (Cures et al. 2001) followed by a helix-turn-helix protein domain (4772 aa) similar to those that make up the DBD. N-terminal truncation of Myb
proteins is observed in multiple oncogenic versions, including v-Myb which is
missing the first 72 amino acids. Additionally, viral integration of the avian
leukosis virus within the 5’end of the Myb gene locus results in a 20 amino acid
N-terminal truncation (Jiang et al. 1997). Both of these N-terminally truncated
proteins result in oncogenic transformation of the infected cells, and just a 20
amino acid N-terminal truncation was the minimal truncation needed to induce
rapid onset of multiple tumor types in chickens (Jiang et al. 1997). More recently
recurrent mutations centered around amino acid 14, were described in pediatric
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T-cell acute lymphoblastic leukemias (Y. Liu et al. 2017). Suggesting the Nterminus of c-Myb has an important role in leashing its oncogenic potential.
Due to the proximity to the DBD past studies have speculated that this
region modulates DNA-binding. Phosphorylation of residues S11 and S12, which
are excluded in the truncated versions discussed above, increased the specificity
of c-Myb by destabilizing DNA-binding (Ramsay, Ishii, and Gonda 1991;
Oelgeschlager et al. 1995). However, this effect could be easily overcome by
protein-to-protein interactions with co-factors that anchored c-Myb to its binding
site on DNA (Oelgeschlager et al. 2001). It is clear that the N-terminus is also
involved in protein-to-protein interactions. To activate the endogenous, chromatin
embedded mim-1 gene c-Myb requires the C/EBPβ(NF-M) co-factor to open the
local chromatin structure, an interaction that was mapped to the N-terminus of cMyb (Oelgeschlager et al. 2001; Introna et al. 1990; Ness et al. 1993). This
region is altered in v-Myb, which is consequently unable to open the local
chromatin structure to activate the endogenous mim-1 gene (Oelgeschläger et al.
1996; Ness et al. 1993). Thus, multiple lines of evidence suggest the N-terminus
of c-Myb proteins has an important function and a role in oncogenicity.
1.4.3 C-terminal truncation
Multiple mechanisms leading to C-terminal truncation of c-Myb have also
been described in human tumors including alternative splicing in leukemais
(Ohyashiki et al. 1988; O’Rourke and Ness 2008), and chromosomal
translocations in adenoid cystic carcinoma (ACC) and glioblastoma
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(Bandopadhayay et al. 2016; A. S. Ho et al. 2013). Multiple studies have
demonstrated C-terminal truncation is also sufficient to convert c-Myb into an
oncogenic version (Cuddihy et al. 1993; Gonda, Buckmaster, and Ramsay 1989;
Fu and Lipsick 1996; Hu et al. 1991). Indeed, only the DBD and TAD, which
maintains the proteins core transactivation ability, are required to block terminal
differentiation of Murine erythroleukemia cells (Cuddihy et al. 1993). Instead the
C-terminus is involved in regulating the activity and specificity of c-Myb. Loss of
this region leads to increased protein stability (Corradini et al. 2005) and
increased transcriptional activity (Fu and Lipsick 1996), and dramatically altered
transcriptional specificity (O’Rourke and Ness 2008; Ness 2003; F. Liu et al.
2006). Loss of these regulatory and specificity region is likely key to oncogenic
activity of C-terminally truncated Myb proteins.
1.4.4 Context specific transcription factor code hypothesis
Initially it was hypothesized that truncated, oncogenic Myb was simply an
activated form of c-Myb, ie it activated the same genes, just better. Instead
further investigations discovered that truncated Myb transcription factors have
completely different transcriptional specificity than full-length c-Myb (Lei et al.
2004; F. Liu et al. 2006). The first evidence that Myb transcription factors had
qualitatively different activities was provided by the endogenous, chromatin
embedded mim-1 gene, which can be activated by c-Myb but not v-Myb
(described in section 1.4.2 (Ness et al. 1993; Introna et al. 1990). Extensive
microarray and reporter assays demonstrated definitively that v-Myb and c-Myb
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had different activities in cells, and appeared to act like completely different
transcription factors in cells (F. Liu et al. 2006). It was hypothesized that the
unstructured C-terminal regulatory domains are involved in extensive protein-toprotein interactions that determine Myb transcription factors specificity, which
was dubbed the transcription factor code hypothesis (Ness 2003). A simplified
illustration of this hypothesis is outlined in Figure 1.5 (adapted from (George and
Ness 2014)), where c-Myb interacts with the blue and green transcription factors
to activate gene A, whereas v-Myb interacts with the orange and tan transcription
factors to activate gene B. The interactions that Myb proteins are able to make
are determined by their N-terminal and C-terminal domains, represented by the
shape of Myb in Figure 1.5. Still, many aspects of the transcription factor code
hypothesis remain unclear, like what co-factors and transcription factors
cooperate with truncated Myb, what genes are activated or silenced, and how
these contribute to cell transformation.
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Figure 1.5. Transcription factor code hypothesis explaining the
transcriptional specificity of Myb proteins.
The transcription specificity of Myb proteins is determine by their N- and Cterminal regulatory domains, represented here as shape. c-Myb interacts with the
blue and green transcription factors to activate gene A, whereas v-Myb interacts
with the orange and tan transcription factors to activate gene B. These interaction
ultimately determine which genes Myb proteins can activate. So c-Myb activates
“normal” genes which are necessary for the proliferation and differentiation of
normal cells. Whereas truncated, oncogenic Myb activates “oncogenic” genes
that lead to uncontrolled proliferation, dedifferentiation, and transformation. The
identity of the cooperating transcription factors and activated genes is not clear.
Figure is adapted from (George and Ness 2014).
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1.5 Myb proteins are the driver oncogenes in adenoid cystic carcinoma
1.5.1 Disease characteristics of adenoid cystic carcinoma (ACC)
With approximately 1200 cases per year in the united states (Allen S. Ho
et al. 2019) ACC is one of the most common tumors that arises in the salivary
gland (Mitani et al. 2011). Tumors are often intractable to current treatments
resulting in a protracted disease course and poor long-term survival between
23% -40% (Hunt 2011; Allen S. Ho et al. 2019). ACC tumors are typified by slow,
yet unpredictable and aggressive growth. Estimates of local disease recurrence
are as high as 100% and late occurring, distant metastases are reported in over
60% of patients (Jones et al. 1997; DeAngelis et al. 2011; Spiro 1997; van der
Wal et al. 2002). ACC tumors also have extremely high incidences of perineural
invasion (Gil et al. 2009), a condition where tumor cells invade the surrounding
nerves. Perineural invasion significantly contributes to patient morbidity and is
associated with local tumor recurrence (Dantas et al. 2015). To date efforts to
develop targeted therapeutic intervention for any aspect of the disease, including
perineural invasion and metastases, have proved unfruitful (Dillon et al. 2016).
Consequently, ACC patients face uncertain outcomes even after initial treatment
due to local recurrence, distant metastases, and lack of targeted therapeutics.
1.5.2 MYB is a human proto-oncogene in ACC tumors
Chromosomal translocations in ACC tumors both activate expression of
the MYB gene and truncate the resulting protein, the two requirements to
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unleash the oncogenic activity of Myb proteins (Nordkvist et al. 1994; M. Persson
et al. 2009). Comprehensive whole genome studies established that ACC tumors
have relatively quiet genomes, with MYB gene mutations being the most
significant mutated pathway by far (A. S. Ho et al. 2013). Early studies estimated
that MYB was the driver oncogene in almost 60% of ACC tumors (A. S. Ho et al.
2013), and estimates have only increased since. Thus, this rare salivary gland
tumor provided the first definitive evidence that truncated Myb proteins are
capable of driving induction and progression of a human tumor.
1.5.3 Characteristics of chromosomal translocations in ACC tumors
The first described, and most common, chromosomal translocation in ACC
tumors occurs between chromosomes 6 and 9, fusing the MYB and NFIB genes
respectively (Figure 1.6A). These chromosomal translocations almost always
result in interruption and truncation of the MYB gene (Brayer et al. 2016), and
produce truncated Myb proteins (Mitani et al. 2011). Chromosomal breakpoints
are scattered throughout the MYB gene ranging from exon 8 to exon 15, with no
apparent hotspots. Importantly, all the identified breakpoints occur after the DBD
and TAD, and were determined to encode functional Myb transcription factors in
reporter assays (Figure 1.6B)(Brayer et al. 2016).
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Figure 1.6. Chromosomal translocations are predicted to produce
transcriptionally active, truncated Myb proteins.
(A) Chromosomal translocations involving normal chromosomes 6 (pink) and 9
(blue) create the fusion chromosome (t(6;9)). Usually the first portion of the MYB
gene (pink) is fused with the last portion of the NFIB gene (blue). (B) Gene
fusions are predicted to produce truncated Myb proteins (protein illustrations).
Some cases are predicted to encode fusion proteins (ex T349 and T013), but
others are predicted to encode frame-shifts that truncate the Myb protein (ex
T399). Chromosomal translocation involving the MYBL1 gene are also predicted
to produce truncated Myb proteins (lower three proteins). All of these truncated or
fused Myb proteins were able to activate expression of a synthetic Myb
responsive promoter (5xMRE). Data for Figure 1.6B was collected by C. Frerich
and published in (Brayer et al. 2016).
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Detailed analyses of RNA-seq fusion transcripts showed that ACC tumors
produce a variety of transcripts, some of which are predicted to encode fusion
proteins while some are predicted to encode premature stop codons. Western
blot analyses have shown that ACC tumors produce truncated Myb proteins
(Mitani et al. 2016), but it is not clear if Myb-NFIB fusion proteins are in fact
present in primary ACC tumors. In 2016 novel chromosomal translocations
involving the related MYBL1 gene were described in ~20% of ACC tumors
(Brayer et al. 2016; Mitani et al. 2016). Again, these chromosomal translocations
most often fused the MYBL1 gene on chromosome 8 to the NFIB gene on
chromosome 9. RNA-seq analyses demonstrated that ACC tumors harboring
MYB t(6;9) and MYBL1 t(8;9) chromosomal translocations had similar gene
expression signatures, indicating these two related transcription factors are
interchangeable driver oncogenes (Brayer et al. 2016).
The full role of chromosomal translocations in activating the MYB gene
and the unleashing the Myb protein is still being revealed. Firstly, chromosomal
translocations serve to truncate the MYB gene, converting c-Myb into an
oncogenic transcription factor. As detailed in the transcription factor code
hypothesis, truncated Myb proteins are predicted to have altered specificity from
full-length c-Myb, and are thus able to drive tumorigenesis. Indeed gene
expression analyses have identified thousands of genes expressed differently in
ACC tumors, yet the critical effects of truncated Myb transcription factors remain
elusive.
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2.1 ABSTRACT
The relative rarity of salivary gland adenoid cystic carcinoma (ACC) and its
slow growing yet aggressive nature has complicated the development of
molecular markers for patient stratification. To analyze molecular differences
linked to the protracted disease course of ACC and metastases that form 5 or
more years after diagnosis, detailed RNA-sequencing (RNA-seq) analysis was
performed on 68 ACC tumor samples, starting with archived, formalin-fixed
paraffin-embedded (FFPE) samples up to 25 years old, so that clinical outcomes
were available. A statistical peak-finding approach was used to classify the
tumors that expressed MYB or MYBL1, which had overlapping gene expression
signatures, from a group that expressed neither oncogene and displayed a
unique phenotype. Expression of MYB or MYBL1 was closely correlated to the
expression of the SOX4 and EN1 genes, suggesting that they are direct targets
of Myb proteins in ACC tumors. Unsupervised hierarchical clustering identified a
subgroup of approximately 20% of patients with exceptionally poor overall
survival (median less than 30 months) and a unique gene expression signature
resembling embryonic stem cells. The results provide a strategy for stratifying
ACC patients and identifying the high-risk, poor-outcome group that are
candidates for personalized therapies.
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2.2 INTRODUCTION
In an era of precision medicine, it has become increasingly important to define
subgroups of patients likely to respond to specific therapeutic strategies. Adenoid
cystic carcinoma (ACC), the second most frequent malignancy of the salivary
glands (Mitani et al. 2011), is a slow growing yet aggressive tumor with a
protracted disease course typified by local recurrence and/or metastasis, which
often occurs 5 or more years after diagnosis (Hunt 2011). The standard treatment
is surgical resection, but the effectiveness in preventing local recurrence and
distant metastases is variable – survival ranges from less than 3 to more than 15
years, suggesting unexplained phenotypic or molecular heterogeneities (Mitani et
al. 2011; D. Bell and Hanna 2012). Efforts to develop targeted treatments have
been largely unfruitful (Dillon et al. 2016), highlighting the need for new and more
effective therapeutic strategies.
ACC has been closely associated with the MYB oncogene since the discovery of
recurrent t(6;9) translocations that fuse the MYB and NFIB genes in many of
these tumors (M. Persson et al. 2009; Mitani et al. 2010; West et al. 2011). The
MYB proto-oncogene encodes a DNA-binding transcription factor implicated in a
variety of human hematopoietic, epithelial and neural malignancies (Ramsay and
Gonda 2008; Y. Zhou and Ness 2011; George and Ness 2014). The recurrent
t(6;9) translocation fuses the MYB gene on chromosome 6 to the NFIB locus on
chromosome 9 and may lead to overexpression of an activated Myb protein or a
novel Myb-NFIB fusion oncoprotein. Detailed epigenetic studies have shown that
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the translocation juxtaposes important enhancers from the NFIB locus to the
MYB gene, leading the oncogene to be aberrantly overexpressed (Drier et al.
2016). However, estimates of the fraction of ACC tumors that harbor the t(6;9)
translocation or that express Myb proteins or MYB-NFIB fusion transcripts have
varied (Mitani et al. 2011; Brill et al. 2011; Fehr et al. 2011; Marta Persson et al.
2012; Pusztaszeri et al. 2014; 2014; Brayer et al. 2016). These discrepancies
may be due to numerous factors, including small cohort sizes, the use of frozen
vs. archival FFPE material from different institutions, different types of detection
methods or even problematic antibodies used in molecular assays. The
confusion has led some authors to conclude that MYB is unlikely to be an
important driver oncogene in ACC tumors (D. Bell et al. 2016)or even that the
fusion partner NFIB plays a more important functional role than expected (Rettig
et al. 2016). These issues became even more complex with the discovery of
alternative translocations in some ACC tumors. For example, instead of fusions
with the MYB gene, a subgroup of ACC tumors display fusions of the MYBL1
gene on chromosome 8, fused to either the NFIB or RAD51B genes (Brayer et al.
2016; Mitani et al. 2016). MYBL1 encodes the A-Myb transcription factor that is
highly related to Myb: the two proteins can bind the same DNA sequences and
can activate the same target genes (Y. Zhou and Ness 2011; George and Ness
2014). Another subgroup of ACC tumors has been described that have point
mutations in NOTCH1 (Ferrarotto et al. 2017). Thus, despite considerable
progress, there remains uncertainty about the extent of heterogeneity amongst
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ACC mutations, the importance of different candidate driver oncogenes in ACC
tumor development and progress and consequently what the appropriate course
of action should be for developing targeted therapeutic agents.
Since metastases in ACC tumors may develop after 5 years or more, linking
molecular data to outcomes is challenging due to the need to analyze relatively
old samples, which may not have been preserved with RNA or DNA analysis in
mind. In addition, there have been reports that several supposed ACC cell lines
have been misidentified or could be contaminated by other cell types, so studies
that have relied primarily on cell line analyses may be compromised (Phuchareon
et al. 2009; M. Zhao et al. 2011). Fortunately, recent advances in the analysis of
RNA derived from archival FFPE samples (Brayer et al. 2016; Brown et al. 2017)
provide a new opportunity to analyze gene expression patterns in rare tumors
like ACC, using primary patient samples that are more than a decade old. Here,
we describe the unbiased RNA-seq analysis of the largest cohort of ACC tumor
samples to date: 68 archival FFPE salivary gland ACC tumors accompanied by
retrospective clinical data, collected over a period of 25 years. The analysis
revealed unforeseen heterogeneity amongst the ACC patients and provided
evidence of diverse molecular signatures amongst ACC tumors as well as genes
associated with poor outcome that could serve as novel biomarkers or targets for
future therapeutic strategies.
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2.3 RESULTS
2.3.1 RNA-seq analysis of ACC tumor samples up to 25 years old
In an earlier study, we compared the RNA-seq profiles of ACC tumors to normal
salivary gland, but many of those tumor samples lacked clinical follow-up data
(Brayer et al. 2016). Many ACC patients survive more than 5 years after surgery
before succumbing to distant metastases, necessitating the analysis of relatively
old samples with informative outcome information. We tested improved RNA-seq
methods (Brayer et al. 2016; Brown et al. 2017), using a small set of ACC
samples collected over a range of dates up to 25 years ago. RNA was isolated
from FFPE sections and analyzed using optimized library methods and the Ion
Proton instrument, which has the advantage of being able to analyze fragments
as short as 25 nt. More than 85% of the initial samples, regardless of their age,
yielded RNA-seq data suitable for our study. We expanded our analysis to 77
samples with follow-up periods of at least 5 years, of which 68 (88%) yielded high
quality RNA-seq results, with an average of ~15 x 10 6 reads for each sample
(Table 2.1). An average of 9% of the reads mapped uniquely to exon features.
These are all new ACC samples, not analyzed in our previous study (Brayer et al.
2016). Figure 2.1A summarizes the number of reads mapped to exons obtained
for each sample, as a function of the years since sample collection. Although
some samples performed better than others, there was not a significant
correlation between the number of high quality, exon mapped reads obtained and
the age of the FFPE samples (R-squared = 0.02). We also performed several
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types of quality control checks on the RNA-seq data and used those results to
eliminate outlier samples (Brown et al. 2017). For example, we compared the
total RNA-seq reads to the exon mapped reads (Figure 2.1B) and the number of
reads in the XIST gene, a female-specific non-coding RNA expressed from the
silenced X-chromosome, as a check of the reported gender information (Figure
2.1C). These results confirmed that RNA-seq can provide useful gene expression
information from FFPE samples, even for archived samples that were collected
more than 10 years ago.
2.3.2 Most ACC tumors express either MYB or MYBL1
Although rearrangements of the MYB and MYBL1 genes have been
observed in many ACC tumors (Brayer et al. 2016), there has been some
controversy about the importance of the oncogenes (D. Bell et al. 2016). In
addition, commercially available antibodies to measure Myb protein levels by
immunohistochemistry can be problematic (data not shown), which could
contribute to some of the reported differences in the fraction of ACC samples that
express Myb proteins. To increase sensitivity, we started with the RNA-seq raw
aligned read (e.g. ‘.bam’) files and used a peak-calling algorithm to identify the
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Figure 2.1. RNA-seq identifies distinct subgroups of ACC tumor samples.
(A) Plot of years since samples were collected vs. RNA-seq reads mapped to
exons in the reference genome shows that high-quality results were obtained
with samples collected up to 24 years ago, and that quality did not correlate with
the age of the samples. (B) Plot of total RNA-seq reads vs. exon mapped reads,
one of the quality control measures employed in this study. (C) Plot of reads
mapped to the XIST gene as a function of reported gender in the associated
clinical data. This quality control step is useful to identify mislabeled samples. (D)
Genome browser representation of peak-calling results generated from ACC
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tumor sample RNA-seq data for the genes indicated. Gene names and
exon/intron structures are at top, arrows show the direction of transcription, each
horizontal line or track is a different ACC sample, ordered to cluster the samples
with similar gene expression patterns and colored bars indicate regions of
transcription detected by the peak-calling algorithm. Note that the MYB gene is
transcribed left-to-right, but the others are right-to-left. Samples that express
MYB (dark blue), MYBL1 (cyan) or neither oncogene (orange) are labeled at left.

Table 2.1. RNA-Seq Statistics
Total Samples, n
Female
Male

68
30
38

Average Total Reads, x10-6 (range)
Average Exon Mapped Reads, x10-6 (range)

15.17 (4.26-27.98)
1.41 (0.34-2.68)

MYB overexpression
MYBL1 overexpression
No MYB or MYBL1

49 (72%)
7 (10%)
12 (18%)
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samples that did or did not express the MYB or MYBL1 genes above
background. The advantage of the peak-calling algorithm is that it also makes
use of the reads that map to intron regions, rather than only the exon-mapped
reads we used for quantifying gene expression (Brayer et al. 2016; Brown et al.
2017). The peak-calling results for these and several other genes are shown in
Figure 2.1D, where colored lines indicate a region of gene expression defined by
the peak-calling algorithm. The results led us to divide the samples into three
groups: 49 of the samples expressed MYB (dark blue, upper samples), 7
expressed MYBL1 (cyan) and 12 expressed neither oncogene (orange, bottom).
Overall, 56 of the 68 samples or 82% expressed either MYB or MYBL1.
Interestingly, none of the samples expressed both MYB and MYBL1, consistent
with the hypothesis that these are the interchangeable driver oncogenes for most
ACC tumors – there is no need or selection pressure for a tumor to express both.
The peak-calling algorithm was able to distinguish many of the samples in which
the MYB or MYBL1 genes were truncated due to translocations (indicated by
shorter lines that fail to extend across the entire gene). For comparison, Figure
2.1D also shows the peak-calling results for several other genes: NFIB and
NOTCH1, which have been implicated as important in ACC tumors and are
expressed in most, but not all of the samples from all three groups, and VGLL3,
an example of a gene that was expressed only in samples that expressed neither
MYB nor MYBL1. The VGLL3 gene encodes a transcription factor implicated in
other epithelial tumors (Gambaro et al. 2013; Tufegdzic et al. 2015), but its
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importance in ACC has not been established. We include it here as an example
only to illustrate the striking differences in gene expression profiles in these
samples. Two of the samples in our cohort did not express NFIB above
background levels, suggesting that NFIB expression is not required for the
development of all ACC tumors (Rettig et al. 2016). However, the samples that
were positive expressed high levels of transcripts, suggesting that at least one
allele of the NFIB gene was very highly expressed in most samples.
2.3.3 Analysis of RNA-seq data for evidence of fusion transcripts
Chromosome translocations and gene fusions are important driver
mutations for many types of leukemia and solid tumors, such as ACC, but their
detection can be problematic. We used several approaches to attempt to identify
potential gene fusions in the ACC tumor RNA-seq data. The peak-calling
algorithm described in Figure 2.1 identified some tumors that appeared to have
truncated oncogenes. A splice-aware aligning program, STAR (Dobin et al.
2013), was used to identify chimeric reads that aligned to two different genes.
Candidates were then verified by visually inspecting the reads using a genome
browser. The results of these efforts are summarized in Table 2.2. Despite the
relatively poor quality of the starting RNA used for these studies, and the modest
read depths obtained, we were able to identify putative chimeric or fusion reads
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Table 2.2. Observed and Putative MYB gene fusions identified in 68 ACC
tumors
Partner 1

Partner 2

Putative Translocation*

No. of
Cases

MYB

NFIB
PDCD1LG2
EFR3A
Fusion partner
unknown

t(6;9)
t(6;9)
t(6;8)
t(6;?)

11
1
1
29

MYBL1

NFIB
Fusion partner
unknown

t(8;9)
t(8;?)

3
4

Tumors with apparent MYB truncation or translocation*
42 (62%)
Tumors with apparent MYBL1 truncation or translocation*
7 (10%)
–
–
Total number of tumors with apparent MYB or MYBL1 translocations* 49 (72%)
Tumors that over-express MYB, but no evidence of truncation
7 (10%)
Tumors that express neither MYB nor MYBL1
12 (18%)
* Based only on RNA-seq results, not confirmed by FISH.
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in a large fraction of the samples. We identified MYB-NFIB fusion reads in 11
samples and MYBL1-NFIB fusion reads in 3 samples. We also identified fusions
between MYB and the PDCD1LG2 or EFR3A genes in two additional samples,
and validated those novel fusions by amplifying them using genomic DNA-based
PCR followed by conventional (Sanger) sequencing (for details and sequencing
results see Supplementary Table S.2.1). We identified 29 samples that appeared
to have truncated MYB gene transcripts where no fusion reads could be found,
so the fusion partner remains uncharacterized. Similarly, 4 samples appeared to
have truncated MYBL1 genes based on the RNA-seq data, but insufficient fusion
reads were found to identify a fusion partner. Although the analysis of RNA-seq
data was able to identify many examples of fusion transcripts, this type of
analysis cannot identify other types of fusions or gene rearrangements that may
not lead to the expression of fusion transcripts, so the percentages of cases with
translocations should be considered an underestimate.
2.3.4 Gene expression signatures identify major subgroups of ACC tumors
In addition to the survival groups described above, our peak-calling
analysis established that ACC tumors form at least three groups, based on the
expression of MYB, MYBL1 or neither oncogene. We characterized the gene
expression signatures in the ACC tumors to investigate the differences or
similarities in these groups. As shown in Figure 2.2A, Principal Components
Analysis separated the ACC tumors into two major groups. The samples that
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Figure 2.2. Differential Gene Expression Analysis: MYB/MYBL1 vs Neither
Oncogene.
(A) Principal components analysis of ACC tumor RNA-seq data. The colors
indicate the samples that express MYB (dark blue), MYBL1 (cyan) or neither of
the oncogenes (orange), as determined by the peak-calling results summarized
in Figure 1D. Note that the orange samples that express neither MYB nor
MYBL1 separate from the others and form their own group on the right side of
the plot. (B) Volcano plot summarizing the differential gene expression analysis,
showing log2 of fold change vs. log10 of the p-value (BH adjusted). See
Materials and Methods for details. (C) The heatmap summarizes the supervised
clustering and differential gene expression analysis comparing the samples
expressing MYB or MYBL1 (marked blue or cyan at top) to the samples
expressing neither oncogene (marked orange at top). The side bar at left
indicates genes that are listed in the drug gene interactions database. Several
interesting genes specific for the two groups are labeled at right. A larger version
of this heatmap with all the genes labeled is provided in the supplementary
results (Supplementary Figure S1).
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expressed neither MYB nor MYBL1 clustered at the right side of the plot
(orange). The remaining tumors expressing either MYB (blue) or MYBL1 (cyan)
were on the left, and completely overlapped, suggesting that the two oncogenes
were interchangeable and contributed to similar gene expression profiles. This is
consistent with previous studies showing that swapping the DNA binding
domains of the c-Myb and A-Myb transcription factors, encoded by the MYB and
MYBL1 genes, respectively, resulted in only minimal changes in specificity and
activity (Lei et al. 2004). The samples that expressed neither MYB nor MYBL1
were specifically re-checked to make sure that they were diagnosed correctly.
Re-examination revealed that all cases were adenoid cystic cancer composed of
tubular and cribriform patients with no solid features. The majority arose from
minor salivary gland sites (see Supplementary Table S2.2).
For differential gene expression analysis, we treated the tumors expressing
either MYB or MYBL1 (dark blue or cyan in Figure 2.2A) as one group and
searched for genes distinguishing them from the tumors expressing neither
oncogene (orange in Figure 2.2A). As shown in the Volcano plot in Figure 2.2B,
our analysis identified more than 1,500 genes that were at least 2-fold up- or
down-regulated, with an adjusted p-value of 0.05 or less. The heatmap shown in
Figure 2.2C summarizes the supervised clustering analysis. The dendrogram
and the color bar at top identify the tumors that express either MYB or MYBL1
(right, dark blue and cyan) and the tumors that express neither oncogene (left,
orange).
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Several important conclusions can be drawn from the heatmap in Figure
2.2C. As described above, the tumors expressing either MYB or MYBL1 do not
form their own groups and do not have distinct gene expression signatures.
Instead, the samples expressing MYBL1 are scattered amongst the MYB
samples, suggesting that the oncogenes are interchangeable and that either can
suffice as the key driver for these tumors. However, there is evidence of
heterogeneity amongst the tumors expressing MYB or MYBL1. Several
subgroups are apparent in the dendrogram at the top, and are especially evident
in the top half of the heatmap, which shows clusters of tumors with different
patterns of gene expression.
Another conclusion is that there are hundreds or thousands of gene
expression differences between the MYB/MYBL1 samples and the tumors that
express neither oncogene. This was unexpected, since all of these tumors are
classified as ACC, but explains why the samples were so easily distinguished in
the principal components analysis (Figure 2.2A). Several interesting genes have
been highlighted and labeled in the heatmap in Figure 2.2C (a full-size version
with all the genes labeled is provided as Supplementary Figure S.2.1). Some of
the most interesting genes up-regulated in the tumors that express neither MYB
nor MYBL1 included JUNB, FOXO1, KLF4, VGLL3, and FOSB, all of which
encode transcription factors and could be potential ‘drivers’ of this ‘non-MYB’
subgroup of ACC tumors. In contrast, the genes correlated most closely with
MYB or MYBL1 expression included chemokine CXXC4 and the transcription
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factors SOX4 and EN1. The latter gene, which encodes the engrailed homeobox
1 transcription factor, has been identified previously as an important biomarker in
ACC tumors (Diana Bell et al. 2012). The SOX4 gene was also identified
previously as being up-regulated in ACC tumors (Frierson et al. 2002). Our
results show that both EN1 and SOX4 are highly correlated with the expression
of MYB/MYBL1, suggesting that they could be direct downstream targets
regulated by the oncogenes.
2.3.5 EN1 and SOX4 are Myb-regulated target genes in ACC tumors
Comprehensive chromatin immunoprecipitation-sequencing (ChIP-seq)
results for ACC tumor samples have been reported (Drier et al. 2016). We
analyzed the publicly available data and confirmed that, although the binding is
weak, both the EN1 and SOX4 promoters are occupied by Myb proteins in ACC
tumors (data not shown). We used PCR to amplify the promoters of each gene,
cloned them into reporter gene plasmids and tested their response to Myb
proteins in transfection/reporter gene assays. Diagrams of the promoter regions
of the EN1 and SOX4 genes are shown in Figure 3.3A, along with the regions
that we cloned into the reporter gene plasmids. Both promoters contain predicted
Myb Response Elements (Ness et al. 1993; Ness, Marknell, and Graf 1989),
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Figure 2.3. EN1 and SOX4 promoter reporter gene assays.
(A) Structure of EN1 and SOX4 promoters and reporter gene vectors. The
diagrams show the 5’-end of each gene with the normal transcription start site
indicated with an arrow and the fragment used for the promoter-reporter
constructs indicated below. Red marks indicate predicted binding sites for Myb
proteins (Myb Response Elements). The full DNA sequence of each cloned
fragment is provided in Methods. (B) Transfection-reporter gene results. The EN1
and SOX4 promoter-reporter gene plasmids were co-transfected into HEK293T
cells along with control (empty) vector or plasmids expressing the normal, fulllength c-Myb or either MYB-NFIB or MYBL1-RAD51B fusion constructs. The
diagrams at left show the structures of the fusion proteins that were expressed.
The bar graph at right shows luciferase reporter gene activity normalized to the
level of control (empty) vector for EN1 (gray) and SOX4 (blue) promoter-reporter
plasmids.
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indicated by red marks in the promoter fragments shown in Figure 3.3A . For
functional assays, we transfected the reporter plasmids into HEK293T cells,
which lack endogenous c-Myb or A-Myb protein expression, along with control
(empty vector) plasmid or plasmids expressing wild type c-Myb or MYB-NFIB or
MYBL1-RAD51B fusion oncogenes identified previously (Brayer et al. 2016). As
shown in Figure 3.3B, both the EN1 (gray) and SOX4 (blue) reporter genes were
strongly (3-14 fold) activated by co-transfection of plasmids expressing wild type
or oncogenic Myb proteins. Neither promoter was significantly activated by a
negative control vector expressing a c-Myb protein with a mutated DNA binding
domain that is unable to bind DNA (not shown). These results confirm that both
the c-Myb protein encoded by the MYB gene and the A-Myb protein encoded by
MYBL1 can activate the EN1 and SOX4 promoters in transfection assays. Based
on these results, the published ChIP-seq results showing that these promoters
are occupied by Myb proteins in ACC tumors, and the tight correlation between
MYB/MYBL1, EN1 and SOX4 RNA levels in ACC tumor samples, we conclude
that EN1 and SOX4 are likely to be direct targets of regulation by Myb proteins in
ACC tumors. However, additional experiments will be required to determine
whether these two Myb-regulated genes play a direct role in the development or
pathogenesis of ACC tumors.
2.3.6 Identification of a high-risk, poor-outcome subgroup of ACC patients
ACC is a morphologically and clinically heterogeneous disease, which
makes grading and treatment challenging. Our previous analyses using only 20
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tumor samples suggested that there was heterogeneity amongst ACC tumors
(Brayer et al. 2016). To investigate this further, we performed unsupervised
hierarchical clustering of the gene expression data for the 68 new tumors,
generating the dendrogram shown in Figure 2.4A. The ACC tumors formed two
major groups. Group 1 (red, n=14) was distinct and separated in the dendrogram,
indicating that the samples were quite different in terms of major gene expression
characteristics. Group 2 (n=54, black and orange) contained the majority of
cases and was composed of several smaller subgroups, implying additional
genetic heterogeneity amongst ACC tumors that could be biologically important.
All of the samples that expressed neither MYB nor MYBL1 (orange) were in the
larger Group 2. We used Kaplan-Meier survival analysis to evaluate all the
samples with survival data (Figure 2.4B), which revealed a median survival for all
ACC patients of 147 months and a 5-year survival rate of 72% (95% Confidence
Interval, C.I.: 0.62-0.84). However, as shown in Figure 2.4C, the 13 patients in
Group 1 (red) with survival information displayed a median survival of only 28
months, a mean survival of only 54% after 2 years (95% Confidence Interval,
C.I.: 0.33-0.89) and a dismal 31% survival over 5 years (95% C.I.: 0.14-0.70).
There were no patients in Group 1 that survived more than 10 yrs. The patients
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Figure 2.4. Identification of a high-risk subgroup of ACC patients.
(A) Unsupervised hierarchical clustering: ACC tumor samples form two major
clusters, labeled Group 1 (red) and Group 2 (orange and black). (B) KaplanMeier survival plot for all 68 ACC tumor samples with survival information
showing median survival (red) as well as 95% confidence intervals (cyan and
dark blue). (C) Kaplan-Meier survival plots of ACC tumor samples in Groups 1
and 2 (red and black, respectively). The groups contained 13 and 55 patients,
respectively. (D) Principal components analysis of ACC tumor RNA-seq data.
The colors indicate the samples that express either MYB or MYBL1 in Group 1
(red) or Group 2 (black) or the samples that express neither of the oncogenes
(orange), as determined by the peak-calling results summarized in Figure 1D.
Note that the samples that express neither MYB nor MYBL1 (orange) separate
from the others and form their own group on the right side of the plot. The poor
survival Group 1 samples (red) cluster at the upper left corner of the plot. (E) The
heatmap summarizes the results of differential gene expression analysis
comparing the poor survival Group 1 (left, red) and better survival Group 2 (right)
ACC samples. The color bar at top indicates samples in Group 1 (red) or
samples that express MYB (dark blue), MYBL1 (cyan) or neither oncogene
(orange). Several interesting genes up-regulated in each group are labeled at
right. A larger version of this heatmap with all the genes labeled is provided in
supplementary information as Supplemental Figure S2.2.
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in Group 2 (black) displayed significantly better survival (log-rank p-value < 1x10 5

) with an average 92% survival over 2 years (95% C.I.: 0.85-1.0), more than

81% survival over 5 years (95% C.I.: 0.71-0.93) and 72% survival over 10 yrs
(95% C.I.: 0.61-0.87). Group 2 contained samples that expressed MYB plus all of
the samples that expressed MYBL1 and all of the samples that expressed neither
oncogene (described in Figure 2.1). When tested separately, all of these
subgroups had relatively good survival. The Principal Components Analysis plot
in Figure 2.4D combines these survival clusters with the results shown above in
Figure 2.2. The ACC samples form three distinct groups: the poor survival Group
1 samples (red) at upper left, the samples that express neither MYB nor MYBL1
at the right (orange), and the remainder of the MYB or MYBL1 expressing
samples at lower left (black). Thus, gene expression patterns identified a
previously unknown subgroup of ACC patients with significantly worse overall
survival and divide the ACC patients into three distinct groups with different driver
oncogenes and outcomes.
A number of publications have reported markers for identifying poor survival
subgroups of ACC patients (Mitani et al. 2011; Diana Bell et al. 2012; Yi, Li, and
Zhou 2016; H. Liu et al. 2015; Phuchareon, van Zante, et al. 2014; Qu et al.
2016; Shao et al. 2011; Zhu et al. 2014; Y. L. Tang et al. 2014; Chang et al. 2016;
Dai et al. 2014). Most of the markers were originally tested using antibody
staining in immunohistochemistry assays, and some were developed using ACC
cell lines whose authenticity have been called into question (Phuchareon et al.
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2009; M. Zhao et al. 2011). We tested whether 20 previously identified markers
were useful for identifying poor survival subgroups in our cohort, using the RNAseq data. The results, summarized in Table 2.3, showed that only MYB, PTK2
(FAK) and SNAI2 (Slug) were useful for identifying subgroups of ACC tumors that
showed significant differences in survival, based on using a Cox proportional
hazard model analysis. None of the other markers yielded significant results,
although the failures could reflect a difference between RNA expression data and
protein expression as measured by immunohistochemistry assays.
We also tested whether any of the other clinical parameters provided with
our cohort of samples could be used to distinguish a poor survival subgroup. As
shown in Table 2.4, we found that age at surgery was significantly associated
with overall survival, when treated as a continuous variable (Hazard Ratio, HR =
1.42 per 10 years). The patients 50 years of age or more had a higher risk than
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Table 2.3. Genes reported to be linked to poor prognosis in ACC tumors
Gene

Reference

Correlated to

Methods*

HR**

BMI1

(Yi, Li, and Zhou 2016)

Poor Outcome

IHC

0.98

0.59

1.61

0.929

CDH1

(Yi, Li, and Zhou 2016)

Good Outcome

IHC

1.08

0.12

9.43

0.945

EN1

(Diana Bell et al. 2012)

Poor Outcome

IHC

2.82

0.66

12.01

0.160

(C. Zhou et al. 2012)

Poor Outcome

QPCR, IHC

0.16

0.02

1.25

0.081

Poor Outcome

QPCR

2.20

0.83

5.81

0.111

ILK

(Phuchareon, Overdevest, et al. 2014)
(H. Liu et al. 2015)

Poor Outcome

IHC

0.57

0.09

3.73

0.555

KIT

(Phuchareon, van Zante, et al. 2014)

Poor Outcome

QPCR

1.13

0.17

7.42

0.897

(Mitani et al. 2011)

Poor Outcome

QPCR

3.59

0.95

13.53

0.059

NOTCH1

(Su et al. 2014)

Poor Outcome

IHC

2.11

0.08

54.54

0.653

PDCD4

(Qi et al. 2013)

Good Outcome

IHC

0.68

0.21

2.26

0.531

(Zhu et al. 2014)

Poor Outcome

IHC

0.57

0.20

1.58

0.277

(Y. Tang et al. 2015)

Poor Outcome

IHC

1.79

0.55

5.84

0.333

PTEN

(H. Liu et al. 2015)

Good Outcome

IHC

0.19

0.01

3.27

0.252

PTK2 (FAK)

(H. Liu et al. 2015)

Poor Outcome

IHC

SNAI1 (Snail)

(Yi, Li, and Zhou 2016)

Poor Outcome

IHC

0.94

0.60

1.47

0.790

SNAI2 (Slug)

Poor Outcome

IHC

0.34

0.13

0.91

0.032

SOD2

(Yi, Li, and Zhou 2016)
(Chang et al. 2016)

Poor Outcome

IHC

0.55

0.10

2.98

0.492

SOX2

(Dai et al. 2014)

Poor Outcome

QPCR

0.65

0.36

1.16

0.144

(C. Zhou et al. 2012)

Poor Outcome

QPCR, IHC

0.85

0.50

1.43

0.529

ZEB2 (SIP1)
Poor Outcome QPCR, IHC
(C. Zhou et al. 2012)
*IHC = Immunohistochemistry; QPCR = Quantitative PCR or other PCR assay.
**HR = Hazard Ratio for one standard deviation increase of gene expression in log scale.

0.48

0.07

3.24

0.453

EPAS1 (HIF2a)
FABP7

MYB

PIM1
PPM1D (WIP1)

TWIST2

95% C.I.

126.26 2.89 5507.29

p-value

0.012

younger patients (HR = 1.34), although the association was not statistically
significant. Gender did not have a significant association with overall survival,
though males had a slightly higher risk than females (HR = 1.27). As might be
expected, the two clinical parameters that describe outcome, Cancer Status
(either NED: No evidence of disease or with tumor) and Metastasis Status (Yes
or No) were both significantly linked to poor survival. Patients with known
metastases had a significantly higher risk than those without (HR = 4.86, p-value
= 0.0008). Patients with tumor had a significantly higher risk than those with no
evidence of disease (NED) (HR = 11.27, p-value = 0.0013).
We used a multivariate analysis to test whether the gene expression groups
provided additional survival information compared to the other variables. As
shown in Table 2.5, gene expression cluster Group 1 was significantly associated
with poor outcome, even after adjusting for the effects of age at surgery and
metastasis status (HR=4.76, p-value < .001). Likewise, age at surgery as a
continuous variable was significantly associated with worse survival after
adjusting for the effects of metastasis status and gene expression cluster (HR =
1.55 per 10 yrs, p-value =.014), and patients with metastases had a significantly
higher risk than those without (HR = 3.18, p-value =.027) after adjusting for the
effects of age at surgery and gene expression cluster. Thus, these three
variables appear to be independently associated with poor survival. Metastasis
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Table 2.4. Characteristics of 68 ACC tumors
Level
N
Age at Surgery, mean
(SD)
Age Group (%)
Gender (%)
Metastasis Status (%)
Cancer Status (%)

<50
50+
Female
Male
No
Yes
NED
With Tumor

Overall
68
50.1 (14.1)

HR*

32 (47.1)
36 (52.9)
30 (44.1)
38 (55.9)
36 (57.1)
27 (42.9)
30 (56.6)
23 (43.4)

MYB + MYBL1
Expression
EN1 Expression

95% C.I.

p-value

1.42
(per 10 yrs)
1
1.34
1
1.27
1
4.86
1
11.27
3.56*

1.07

1.87

0.0143

0.63

2.86

0.4513

0.58

2.74

0.5516

1.93

12.21

0.0008

2.57
0.71

49.51
17.91

0.0013
0.123

2.82*

0.66

12.01

0.1603

Key: HR = hazard ratio; C.I. = Confidence Interval; p-value = p-value of Wald test
based on Cox-regression; NED = No Evidence of Disease
*HR = Hazard Ratio resulted in by one standard deviation increase

Table 2.5. Multivariate Cox-Regression Analysis
Level

HR

No
Yes
Group 2
Group 1

1.55*
(per 10 yrs)
1
3.18
1
4.76

N
Age at Surgery
Metastasis Status
Gene Expression Cluster

95% C.I.

p-value

1.10

2.20

0.014

1.14

8.87

0.027

1.93

11.77

<0.001

Key: HR = hazard ratio; C.I. = Confidence Interval; p-value = p-value of Wald test
based on Cox-regression
* Hazard Ratio associated with 10-year increase in age.
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Status is an outcome marker that is evaluated years after surgery and describes
the success of the treatment. In contrast, the gene expression patterns were
determined from surgical samples that were collected before the outcomes were
known. So information about molecular differences could be useful for predicting
overall survival and for identifying patients that need different treatment
strategies or who could benefit from more intensive follow-up care.
2.3.7 Gene expression signatures define good- and poor-outcome subgroups of
ACC patients
We performed differential gene expression analysis using the groups of
ACC tumors identified by hierarchical clustering, and identified over 2,000 genes
that were significantly (at least 2-fold up or down, adjusted p-val < 0.05) different
between the two survival groups. The heatmap in Figure 2.4E compares the
expression of the 100 genes that were most significantly correlated to Group 1
(poor survival, left, color bar: red) or Group 2 (better survival, right, color bar:
orange, blue or cyan). Genes up-regulated in the poor survival group included
IPO9, ERBB3, SOX4, MYB and GABRP. Genes up-regulated in the better
survival group included SETBP1, EGFR, TP63 and PIGR (A full-sized heatmap
with all the genes labeled is provided as Supplementary Figure S.2.2). The
differential expression of ERBB3 and EGFR in the poor and good survival
groups, respectively, suggests a difference in signaling pathways linked to
epithelial to mesenchymal transition. Although WNT signature genes were not
significantly enriched in our pathway analyses, several genes in the WNT
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signaling pathway were differentially expressed, suggesting that a WNT specific
signature may be important for the differences between the good- and pooroutcome groups. However, this characterization will require additional study.
2.3.7 A stem cell gene expression signature is associated with poor outcome
We used Gene Set Enrichment Analysis (Subramanian et al. 2005) to
illuminate the differences between the poor and good outcome subgroups of
ACC tumors. A straightforward comparison of the two groups, using the
differentially expressed genes for all 68 tumor samples (Figure 2.4E), did not
identify any significantly enriched pathways, perhaps because of the dramatic
heterogeneity within the good outcome group, which contained samples
expressing MYB, MYBL1 and neither oncogene. Therefore, since all of the Group
1 samples expressed MYB, we focused our analysis by comparing them only to
the other samples expressing MYB. Principal Components Analysis (Figure 2.5A)
cleanly separated the 13 samples in the poor outcome Group 1 (red, left) from
the 36 MYB expressing samples in the better outcome Group 2 (blue, right).
Using the approximately 1,000 genes that were significantly differentially
expressed between the two groups of MYB expressing tumors, Gene Set
Enrichment Analysis identified several gene lists that were enriched in the Group
2, good outcome samples (Table 2.6). However, only one gene list was
significantly enriched in the poor outcome group (Table 2.7). As shown in Figure
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Figure 2.5. Gene Set Enrichment Analysis of MYB Samples
(A) Principal Components Analysis of the MYB expressing samples. The colors
indicate the samples in Group 1 (red, left) or Group 2 (blue, right). Note that the
poor survival Group 1 samples form their own group on the left side of the plot.
(B) Enrichment Plot of gene set ‘Benporath_ES_with_H3K27me3’ identified using
the genes differentially expressed between the Group 1 and Group 2 samples
expressing MYB. (C) Heatmap of differentially expressed genes from gene set

53

‘Benporath_ES_with_H3K27me3’, identified through Gene Set Enrichment
Analysis.
Table 2.6. Gene Set Enrichment Analysis Results – Group 2
ENRICHED IN GROUP 2 (GOOD OUTCOME)

GENESET NAME

SIZE

NOM p-val

FDR q-val

LIM_MAMMARY_STEM_CELL_UP

41

0

0

LIU_PROSTATE_CANCER_DN

42

0

6.08E-04

SENESE_HDAC1_AND_HDAC2_TARGETS_DN

18

0

0.008256009

WANG_SMARCE1_TARGETS_UP

24

0

0.011867385

ONDER_CDH1_TARGETS_2_DN

32

0

0.013505637

MCBRYAN_PUBERTAL_TGFB1_TARGETS_UP

15

0

0.017456258

FORTSCHEGGER_PHF8_TARGETS_DN

18

0

0.022528453

ACEVEDO_FGFR1_TARGETS_IN_PROSTATE_CANCER_MODEL_DN

23

0.001287001

0.022527734

TURASHVILI_BREAST_DUCTAL_CARCINOMA_VS_DUCTAL_NORMA
L_DN

29

0.001305483

0.040243994

CHANDRAN_METASTASIS_DN

15

0.001461988

0.02578634

KOINUMA_TARGETS_OF_SMAD2_OR_SMAD3

33

0.002597403

0.05427582

KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_DN

22

0.004166667

0.052254837

PASINI_SUZ12_TARGETS_DN

17

0.004279601

0.034044717

MARTINEZ_RB1_AND_TP53_TARGETS_UP

15

0.005763689

0.07122304

BRUINS_UVC_RESPONSE_LATE

27

0.006648936

0.06798041

JAEGER_METASTASIS_DN

22

0.008310249

0.06001583

CHICAS_RB1_TARGETS_CONFLUENT

33

0.008782936

0.07140977

Table 2.7. Gene Set Enrichment Analysis Results – Group 1
ENRICHED IN GROUP 1 (POOR OUTCOME)

GENESET NAME

SIZE

NOM p-val

FDR q-val

BENPORATH_ES_WITH_H3K27ME3

22

0.003861004

0.10307397
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5B, the genelist “BENPORATH_ES_WITH_H3K27ME3” was significantly (pval <
0.004) enriched in Group 1. This genelist is described as “genes possessing the
trimethylated H3K27 (H3K27me3) mark in their promoters in human embryonic
stem cells, as identified by ChIP on chip” (Ben-Porath et al. 2008). This suggests
that the poor outcome tumors display features related to ES cells, similar to highgrade estrogen receptor-negative, basal-like breast tumors, which also have poor
clinical outcome (Ben-Porath et al. 2008). The heatmap in Figure 2.5C
summarizes the expression of the genes in this list in the Group 1 (left, red) and
Group 2 (blue, right) tumors. The poor outcome samples are distinguished by
their relatively high expression of SOX8, MYB and TGFA and low expression of
SYNE1, TBX3 and PTPRT. These results suggest that a gene expression
biomarker could be developed to identify patients in the high-risk, poor-outcome
group so they could be stratified for more intensive follow up to improve survival.

2.4 DISCUSSION
ACC is representative of a large class of relatively rare tumors that are
difficult to study because of limited samples, lack of validated cell lines and
undeveloped tumor models. In the case of ACC, the disease course can be slow,
often resulting in the development of metastases 5 or more years after diagnosis
and surgery (Hunt 2011). This necessitates the study of relatively old samples so
that molecular information can be correlated to clinical outcomes. To address this
issue, we developed optimized RNA-seq approaches (Brayer et al. 2016; Brown
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et al. 2017) so that the gene expression patterns in archived, FFPE samples up
to 25 years old can be analyzed in detail. By applying these methods to one of
the largest cohorts of ACC samples ever studied, we uncovered several
important subsets of ACC patients and illuminated new molecular details about
the oncogenic drivers that could be targeted by new types of therapeutic
approaches.
We applied a novel use of a statistical peak-calling algorithm to identify the
ACC samples that expressed MYB, MYBL1 or neither oncogene. In addition to
identifying three subgroups of ACC tumors, this approach showed that no ACC
tumors in our cohort expressed both MYB and MYBL1, which is consistent with
our model that the two oncogenes are interchangeable drivers of tumorigenesis
(Brayer et al. 2016). With the subgroups of ACC tumors cleanly separated, we
were able to perform differential gene expression analysis to identify gene
expression signatures characteristic of each group. The ~80% of tumors that
expressed either MYB or MYBL1 displayed dramatically different gene
expression profiles than the tumors that expressed neither of the oncogenes
(Figure 2.2). Of particular note were the EN1 (engrailed) and SOX4 genes that
were highly correlated to the expression of MYB/MYBL1. We investigated these
two genes that encode transcription factors, and found that the promoters of both
genes have predicted Myb Response Elements and were activated by ectopically
expressed c-Myb or A-Myb proteins in transfection-reporter gene assays.
Coupled with the published ChIP-seq data showing that the promoters are
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occupied by Myb proteins in ACC tumors (Drier et al. 2016), we conclude that
both EN1 and SOX4 are likely to be direct target genes activated by the
MYB/MYBL1 oncogene products in ACC tumors that express one of the
oncogenes.
The other group of ACC tumors express neither MYB nor MYBL1 and also
do not express EN1 or SOX4. Instead, they express oncogenic transcription
factors KLF4, FOXO1, JUNB and FOSB and the important developmental
regulator VGLL3. There is currently no other supporting evidence indicating that
the products of these genes act as drivers of tumorigenesis in this subgroup of
ACC tumors, but they seem like excellent candidates for further study and
perhaps the development of animal models to test their activities.
Because of the heterogeneity we observed in the gene expression patterns
in ACC tumors, we applied unsupervised hierarchical clustering to the RNA-seq
results from our cohort of 68 ACC samples and unexpectedly identified a
subgroup of tumors with significantly worse overall survival (Figure 2.4). The 68
patients that we studied included 25 who failed to survive 10 years, and more
than half of those were in the poor survival subgroup identified by hierarchical
clustering. The poor survival group over-expressed ERBB3 and under-expressed
EGFR, suggesting that poor survival may be linked to epithelial-to-mesenchymal
transition or to myoepithelial vs epithelial phenotype. The poor survival samples
also over-expressed CTNNB1 and SOX4 and under-expressed PIK3R1 and
TP63, all of which have been linked to tumorigenesis in other cancers. We tested
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20 different markers that had been reported by others to be able to distinguish
poor survival ACC tumors, but only three, MYB, PTK2 (Fak) and SNAI2 (Slug),
showed significant differences in our cohort (Table 2.3). This probably reflects the
differences in assays used – RNA levels in our assays compared to
immunohistochemistry in most of the publications – but should raise a warning
flag to others who wish to compare published results with studies using different
technologies.
Perhaps the most important finding from these studies is the use of RNAseq and gene expression patterns to identify a high-risk, poor-survival subgroup
of ACC patients that were previously unidentified. These patients are the ones
that could benefit most from increased surveillance and the development of new
types of therapeutic strategies, such as targeted therapies that inactivate the
MYB oncogene (Uttarkar, Dassé, et al. 2016; Uttarkar, Piontek, et al. 2016). The
development of improved biomarkers to identify the highest-risk patients could
lead to important improvements in the treatment of ACC tumors.

2.5 METHODS
2.5.1 Human Salivary Gland ACC FFPE samples
De-identified salivary gland adenoid cystic carcinoma FFPE tumor samples
were obtained from the Salivary Gland Tumor Biorepository (MD Anderson
Cancer Center, Houston, TX; Table 2.1). A search of MD Anderson Head and
Neck tumor bank for salivary gland adenoid cystic carcinoma led to the
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identification of 100 patients with primary section at our institution. Hematoxylin
and eosin stained slides of all tumors were retrieved and were subjected to an
independent, blinded review by two specialized head and neck pathologists. The
phenotypic assessment of ACC was strictly made on the histopathologic finding
of tubular and cribriform patterns with dual cellular formation and light luminal
polysaccharide secretion with and without solid component. Tumor with solid
form lacking tubular/cribriform foci were not included. The review confirmed the
diagnosis of ACC in all tumors. Due to the long disease course for ACC tumors,
samples were chosen that had at least 5 yr follow-up. All samples were collected
with informed consent of the donors, and studies were conducted in accordance
with the principle of the Declaration of Helsinki. All studies were performed with
Institutional Review Board-approved protocols.
2.5.2 RNA Isolation and Sequencing
Total RNA was isolated from one or two 5-micron slide-mounted FFPE
sections using the RNeasy FFPE kit (Qiagen). cDNA synthesis and library
preparation were performed using the SMARTer Universal Low Input RNA Kit for
Sequencing (Clontech) and the Ion Plus Fragment Library Kit (Life Technologies)
as previously described (Brayer et al. 2016). Sequencing was performed using
the Ion Proton and Ion S5/XL systems (Life Technologies) in the Analytical and
Translational Genomics Shared Resource at the University of New Mexico
Comprehensive Cancer Center. RNA sequencing data is available for download
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from the NCBI BioProject database using study accession number
PRJNA287156.
2.5.3 Data Analysis
Low quality and non-human RNA-seq reads were identified and removed
from the analysis pipeline using the Kraken suite of quality control tools (Davis et
al. 2013; Wood and Salzberg 2014). High-quality, trimmed, human RNA-seq
reads were aligned to the human genome (GRCh37; hg19) using TMAP (v5.0.7)
and gene counts were calculated using HT-Seq as previously described (Brayer
et al. 2016) Poor quality samples, defined as those samples which had fewer
than 10% of the median number of reads of all samples, were removed from
further analyses. Several additional samples were removed based on the quality
control measures described in the text. Peak finding to identify samples that
expressed MYB or MYBL1 was performed using findpeaks from the HOMER
(v4.9) package (Heinz et al. 2010), with settings of -region, -size 1000 and minDist 10000.
2.5.4 Unsupervised hierarchical clustering
Analyses were limited to genes that were highly expressed above a
threshold level in a number of samples (e.g. 250 reads in at least 10 samples).
Hierarchical clustering was performed on an expression matrix of 882 highly
expressed genes in 68 ACC tumors with the Euclidean distance as the
dissimilarity measure and the default “complete” clustering method from the
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hclust command in the package stats, part of statistical software R/Bioconductor
(Gentleman et al. 2004). Genes that correlated with molecular subgroup were
discovered using the samr R package (Jun Li et al. 2012; J. Li and Tibshirani
2013) to identify genes positively and negatively correlated with the first and
second dimensions of a PCA plot describing these data (Tusher, Tibshirani, and
Chu 2001).
2.5.5 Statistical Analysis
The primary endpoint for the outcome was overall survival (OS), defined
as time from the date of diagnosis to the date of death. Subjects who were lost to
follow-up or alive within the follow-up period were censored at the date of the last
contact. The OS was estimated using the Kaplan-Meier method, and the
differences in OS were examined using the log-rank test. Univariate Cox
regression was used to assess the associations of clinical characteristics or
genomic features with survival outcome, and multivariate Cox regression was
used to compare amongst these variables. All the statistical analyses were
performed using statistical software R (Tusher, Tibshirani, and Chu 2001).
2.5.6 Translocation Verification
For detection of putative fusions, samples with apparent MYB or MYBL1
translocations, evidenced by a lack of reads mapped to the 3' end of the gene,
were examined for chimeric reads containing sequence matching the MYB or
MYBL1 gene and another gene. Chimeric reads were detected using the
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Integrative Genomics Viewer (version 2.3.79) (Thorvaldsdóttir, Robinson, and
Mesirov 2013) with "show soft clips" turned on, and then secondarily aligned to
GRCh37/hg19 using BLAT at the UCSC genome browser (Karolchik, Hinrichs,
and Kent 2007; Kent et al. 2002) to determine the translocation partner. Samples
that had obvious truncations but for which no chimeric reads were identified,
were categorized as "unknown”. Novel translocations were verified by RT-PCR
amplification of RNA isolated from FFPE slices as previously described (Brayer
et al. 2016). Gene-specific primers used to amplify cDNA and resulting Sanger
sequences are provided in Supplementary Table S.2.1.
2.5.7 EN1 and SOX4 Promoter Fragments
Fragments of the human EN1 and SOX4 gene promoters were isolated by
PCR amplification from genomic DNA and cloned into the pGL3-basic reporter
backbone. A 345 bp fragment of the EN1 promoter was amplified (forward: 5’GAGGAGGAGCTCGAGAACGTAAACTGTCGACGC, reverse: 5’GAGGAGGAGAAGCTTAGAGAAATGCAGGATTATGGGTC) and cloned using
XhoI and HindIII restriction sites included in the primers. Similarly, a 161 bp
fragment of the SOX4 promoter was amplified (forward: 5’GAGGAGGAGGCTAGCTGCAGCCAAGACTGTGAAAG, reverse: 5’GAGGAGGAGCTCGAGAGGAGTTCCTCCAGTGCAGA) and cloned using XhoI
and NheI restriction sites. Insert sequences were verified via conventional
(Sanger) sequencing.
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Insert sequences were verified via conventional (Sanger) sequencing.
Underlined portions are untranslated regions. Predicted Myb binding motifs are in
bold+underlined. Genomic coordinates (hg19) of the inserts are shown. The EN1
promoter fragment that we cloned contains a common polymorphism
(rs3731613) compared to the reference hg19 sequence, indicated by a lower
case ‘g’.
>SOX4-luc chr6: 21593929-21594089
GCTGCAGCCAAGACTGTGAAAGGATAAAGAGGCGCGAGGCGGAATTGGGGTCTGCTCTAA
GCTGCAGCAAGAGAAACTGTGTGTGAGGGGAAGAGGCCTGTTTCGCTGTCGGGTCTCTAG
TTCTTGCACGCTCTTTAAGAGTCTGCACTGGAGGAACTCCT
>EN1-luc chr2: 119605727-119606071
AACGTAAACGTGCGACGCTAGCTAGGCGCAGCGGGCCTTTCAGATTTTGCTATTTGTGAA
AAACAAATTGCGCCTCTGAAAGTAACCAACTCTAGGTCTATTTCACATCACCGACCTCCC
TGTCTCACTCCCCCTCCCTCCACTACACACACCCAAACCCACACCCACCCACAAACACAC
AAACCGGCAGTGACAACAACCACCCATCCTTCAATAACAGCAACCAGAGACAGAGGAGAA
AATAAAAAGCTGAGTTTCTTAGGCGTGGGGGTGCAAAACAGCCAGGCTCCTGCCTACTGC
CCCTGCTCCCGgAGCTCACAGACCCATAATCCTGCATTTCTCTAA
2.5.7 Transfections and reporter gene assays
MYB and MYBL1 fusion expression vectors, cloned into pCDNA3, were
described previously (Brayer et al. 2016). Specifically the c-Myb:NFIB fusion
contains a cDNA fragment spanning exons 1-8s (O’Rourke and Ness 2008; Y.
Zhou et al. 2011) of MYB (NM_001130173) encoding the first 313 aa of c-Myb
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fused to exons 10-11 of NFIB (NM_001282787), which adds 73 novel amino acid
residues to the truncated Myb protein. The A-Myb:RAD51B fusion contains exons
1-9 of MYBL1 (NM_001080416) encoding the first 367 aa of A-Myb fused to an
intronic region of RAD51B, which adds 28 novel amino acids to the truncated AMyb protein. Reporter gene assays were performed in HEK293T cells in
triplicate. Cells were seeded at approximately 4 to 6 x 10 4 cells per well in a 24
well plate and allowed 24 hours growth before transient co-transfection with 50
ng of luciferase reporter plasmid (EN1-luc or SOX4-luc in pGL3-basic) and 5 ng
of activator plasmid (MYB or MYBL1 fusions cloned into pCDNA3). Transfections
were performed in duplicate using the TransIT-2020 transfection (Mirus) reagent
according to the manufacturer’s instructions. Cells were harvested and
luminescence was measured after 48 hours using the Luciferase Assay System
(Promega). Background subtracted data were normalized to cells transfected
with the reporter plasmid and no activator (empty pCDNA3). All experiments
were performed at least in triplicate.
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3.1 ABSTRACT
Adenoid cystic carcinoma (ACC) is an aggressive salivary gland tumor
that tends to infiltrate surrounding nerves. Most ACC tumors overexpress the
MYB gene, making it the predicted driver oncogene, but chromosomal
translocations only occur in half those cases. We found by RNA-sequencing
analyses and mapping the 5’-ends of MYB transcripts that ACC tumors
preferentially utilized an alternative MYB promoter, a novel mechanism of MYB
gene activation in ACC. Nearly all ACC tumors used the alternative promoter, but
other tumor types did not. Alternative promoter use produces N-terminally
truncated Myb proteins which activated cell type specific MYB promoters in
reporter assays. N-terminally truncated Myb isoforms displayed unique
transcriptional activities, regulating many genes differently than full-length Myb.
This Myb isoform uniquely regulated genes associated with pro-tumorigenic
neural migration signals and perineural invasion, a feature associated with poor
prognosis in ACC tumors. Thus, a regulatory pathway unique to ACC activates
the alternative MYB promoter, leading to production of a truncated Myb protein
with altered transcriptional activities. This study has important implications for
future studies targeting MYB gene activation in ACC.

3.2 STATEMENT OF SIGNIFICANCE
The majority of MYB-expressing ACC tumors preferentially use a rarely used
alternative MYB promoter, producing Myb proteins with an N-terminal deletion
67

and significantly altered transcriptional specificity. These results implicate Myb in
promoting perineural invasion and have important implications for developing
targeted therapeutics aiming to disrupt MYB gene expression in ACC tumors.

68

3.3 INTRODUCTION
Adenoid cystic carcinoma (ACC) is an unpredictable and aggressive
malignancy which most frequently occurs in the salivary gland. Estimates of local
recurrence are as high as 100% and late occurring, distant metastases are
reported in over 60% of patients (Jones et al. 1997; DeAngelis et al. 2011; Spiro
1997; van der Wal et al. 2002). ACC tumors have one of the highest incidences
of perineural invasion (Gil et al. 2009), a condition where tumor cells invade the
surrounding nerves, and is associated with local tumor recurrence (Dantas et al.
2015). Recent studies have revealed previously unappreciated diversity amongst
ACC tumors, with gene expression analyses exposing a poor-outcome patient
group with a median survival of little more than 2 years (Frerich et al. 2018).
Consequently, ACC patients face uncertain outcomes even after initial treatment
due to local recurrence, distant metastases, lack of targeted therapeutics, and
intrinsic tumor diversity. Hallmark chromosomal translocations activate the
related MYB or MYBL1 genes, indicating that these are the essential drivers in
ACC tumors (Frerich et al. 2018; Brayer et al. 2016; Gao et al. 2014; Mitani et al.
2010; 2016). Many chromosomal translocations involve the NFIB gene, creating
t(6;9) and t(8;9) fusions for the MYB and MYBL1 genes respectively, but less
frequent translocations involving other genes occur as well (Frerich et al. 2018).
Together, the activated MYB and MYBL1 oncogenes appear to be responsible for
oncogenesis in over 80% of ACC tumors (Frerich et al. 2018). Over 70% of ACC
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tumors, including the most aggressive, poor-outcome tumors (Frerich et al.
2018), overexpress MYB and the encoded Myb transcription factor.
The Myb transcription factor regulates the expression of thousands of
genes to coordinate proliferative and differentiated cell states in multiple normal
cell types (Brayer et al. 2016; Quintana et al. 2011; Mucenski et al. 1991;
Matsumoto et al. 2016). Indeed, Myb is implicated in ensuring normal salivary
gland development (Matsumoto et al. 2016), the tissue in which ACC tumors
most often arise. Myb has also been implicated in numerous other malignancies
(George and Ness 2014; Y. Zhou and Ness 2011), where C-terminal truncations
to the Myb protein are necessary to unleash its oncogenic and transforming
ability (Hu et al. 1991; Ramsay, Ishii, and Gonda 1991; Lei et al. 2004; Fu and
Lipsick 1996). For instance, in pediatric leukemias enhanced alternative RNA
splicing of MYB gene transcripts appears to produce truncated, activated
isoforms of the Myb protein that may contribute to oncogenesis (Y. Zhou et al.
2011). Similarly, in many ACC tumors, chromosomal translocations break the
MYB gene producing C-terminally truncated, oncogenic isoforms of Myb proteins.
Chromosomal translocations are further implicated in activating expression of the
MYB gene by recruiting distant enhancers linked to its translocation partner NFIB
to interact with the conventional MYB promoter, thus stimulating expression of
the MYB gene (Drier et al. 2016). The recruited NFIB enhancers also appeared
to be activated by Myb proteins themselves, creating an oncogenic feedback
loop enforcing expression of the MYB oncogene in ACC tumors (Drier et al.
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2016). Thus, chromosomal translocations and enhancer hijacking are thought to
be the primary mechanism activating the MYB gene. However, the MYB gene is
highly over-expressed in most ACC tumors, even those without evidence of
chromosomal translocations, raising the possibility that there are additional
unknown mechanisms by which these tumors activate expression of MYB
(Frerich et al. 2018).
Transcription of the MYB gene is tightly controlled and highly regulated
throughout development in different tissues. The conventional promoter,
upstream of exon 1, responds to a variety of stimuli (Lauder, Castellanos, and
Weston 2001; Drabsch et al. 2007; H. J. Hugo et al. 2013; Cesi et al. 2011). For
example, in T-cells NF-κB binding of this MYB promoter following IL-2 stimulation
allows proliferation and protects from apoptosis (Lauder, Castellanos, and
Weston 2001). In some tissues, MYB expression is also tightly regulated by a
well-described transcriptional pause site in the first intron (J. Zhang et al. 2016;
Perkel, Simon, and Rao 2002; Yuan 2000; H. Hugo et al. 2006; Suhasini and Pilz
1999; Pereira et al. 2015). Specifically, RNA polymerase stalling must be relieved
to allow MYB expression in breast cancer where binding of estrogen receptor
releases attenuation and allows MYB expression (Drabsch et al. 2007). In normal
proliferating erythroid cells this entire region, from the promoter through the
length of the first intron, interacts with multiple distant enhancer elements forming
a dynamic active chromatin hub (Stadhouders et al. 2014).
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Additionally, an alternative MYB promoter immediately upstream of the
second exon has been implicated in aberrant expression of MYB in some
leukemia cell lines (Dassé et al. 2012; Jacobs, Gorse, and Westin 1994).
Genome-wide studies estimate that half of the expressed human genes have
multiple promoters, with an average of 4 promoters per gene, and it is
increasingly clear that alternative promoter use is an important regulatory
mechanism to increase transcript and protein diversity (X. Wang et al. 2016).
Promoter selection is regulated in a developmental-stage, cell-type, and diseasespecific manner. Widespread promoter switching is observed during normal
cerebellar development, where ~20% of genes display differential promoter
usage (P. Zhang et al. 2017), and ~80% of human transcription start sites are
classified as cell-type specific in the FANTOM5 promoter atlas (Forrest et al.
2014). Aberrant alternative promoter activation was first implicated in
oncogenesis at least 25 years ago (Marcu, Bossone, and Patel 1992), and
evidence of its role in tumorigenesis has continued to increase (Davuluri et al.
2008; Northcott et al. 2014; Weischenfeldt et al. 2017). These studies indicate
that the alternative MYB promoter may have an unappreciated importance in
MYB driven disease.
Transcriptional regulation of the MYB gene is tightly controlled in
developing cells and silenced in mature, differentiated, non-proliferative cells.
Those normal regulatory mechanisms are hijacked or circumvented in tumors to
allow overexpression of oncogenic Myb proteins. In ACC unique, tumor-specific
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interactions between a hijacked enhancer and the MYB gene promoter could
provide a novel target for therapeutic intervention. However, MYB is also highly
over-expressed in ACC tumors that do not have chromosomal translocations,
and the mechanism of MYB activation in these tumors is unclear. Thus, we
sought to investigate in detail regulation of the MYB gene in ACC tumors.
Surprisingly, we found that the majority of ACC tumors utilize a normally silent
alternative promoter located in the first intron of the MYB gene. These results
have important implications for devising possible strategies to disrupt Myb-driven
oncogenesis that leads to ACC tumor formation.
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3.4 RESULTS
3.4.1 ACC tumors express MYB from an alternative promoter
Many studies have established that the MYB gene is an important
oncogene in ACC tumors. Most of these studies have focused on hallmark
chromosomal translocations involving the MYB gene and their downstream
consequences. In the course of our previous RNA-sequencing (RNA-seq) studies
of ACC tumors (Frerich et al. 2018; Brayer et al. 2016) we observed that there
are typically very few reads aligned to the first exon of the MYB gene, indicating
an anomaly in its transcriptional regulation. However, little regarding the
transcriptional regulation of the MYB gene in ACC tumors has been studied. In
other tissues and cell types transcriptional regulation of the gene is tightly
controlled through multiple mechanisms centered around the extreme 5’ end of
the gene (see the gene track below the RNA-seq data; Figure 3.1A)(Lauder,
Castellanos, and Weston 2001; Drabsch et al. 2007; J. Zhang et al. 2016).
Transcription typically begins at the conventional promoter (TSS) in the region
directly upstream of exon 1 (Figure 3.1A). Downstream of TSS1, within intron 1 is
a regulatory RNA polymerase II pause site (hairpin structure) and an infrequently
used alternative promoter, designated here as TSS2 (Figure 3.1A) (Dassé et al.
2012; Jacobs, Gorse, and Westin 1994)).
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Figure 3.1: ACC tumors use an alternative MYB gene promoter.
(A) RNA-seq from two ACC tumor is displayed in IGV. Aligned reads are
displayed as gray peaks exons. Spliced reads displayed as read arcs with the
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raw number of spliced reads above the arcs. In most cell types, MYB
transcription begins at TSS1 upstream of exon 1. The first intron contains the
RNA-polymerase attenuation site (hairpin structure) and an alternative promoter
(TSS2, second bent arrow). There are few reads aligned to exon 1 (gray peaks
above the gene track) in two ACC tumors (T73 and T9), and many more reads
aligned to exon 2. (B) 5’RLM-RACE performed on a frozen ACC tumor sample
(T73) revealed transcripts from both TSS1 (designated +1 nt, RefSeq
NM_005375) and TSS2 (GenBank X52126). Multiple transcription start sites
were observed for TSS2, at +4409 nt and +4569 nt, creating a 180 nt and 20 nt
5’UTR respectively.
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Transcription then continues to exons 3 and 4 and so on. In light of our previous
observations that there may be an anomaly in transcriptional regulation of the
MYB gene in ACC tumors we visually inspected RNA-seq reads derived from two
frozen ACC tumors (T73 & T9, Figure 3.1A). RNA-seq coverage of the first 4
exons of the MYB gene is shown using the Integrative Genome Browser (IGV) in
Figure 3.1A. The aligned RNA-seq reads are displayed as gray peaks and the
number of reads spanning a splice junction are indicated above the
corresponding red arc (Figure 3.1A). We chose RNA-seq from frozen tumors to
mitigate sequencing artifacts present in low quality formaldehyde fixed paraffin
embedded (FFPE) samples. Again we found markedly fewer reads aligned to
exon 1 in compared to exon 2. Further, the number of reads in both samples that
splice from exon 1 to exon 2 is drastically lower than those that splice from exon
2 to exon 3 (the raw number of reads is indicated above arcs which are displayed
proportionally, Figure 3.1A). If transcription in these tumors began at TSS1 and
continued through the remainder of the gene the number of reads aligned to
exon 1 and exon 2 should be approximately equal. Alternatively, if transcription
began at TSS1 and the RNA polymerase stalled at the regulatory hairpin
structure within intron 1, a buildup of reads upstream of the hairpin followed by
many fewer reads on exon 2 would be expected. However, we observed many
more reads on exon 2 than exon 1, which is most consistent with transcription
skipping TSS1 and instead beginning at TSS2 (Figure 3.1A, TSS2).
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To confirm these observations were due to TSS2 use and not simply an
artifact of sequencing depth and/or quality we mapped the 5’-ends of transcripts
in ACC T73 using RNA-ligase mediated rapid amplification of cDNA ends
(5’RLM-RACE) followed by conventional ‘Sanger’ sequencing (Figure 3.1B).
5’RLM-RACE specifically discovers the extreme 5’ ends of completely processed
mRNA transcripts and can be used to infer promoter location and transcription
start sites. Using 5’RLM-RACE in ACC T73 we identified transcripts originating
from the expected TSS1 (see the corresponding RNA-seq in Figure 3.1A), the
promoter directly upstream of exon 1 (Figure 3.1B, MYB TSS1; RefSeq ID
NM_005375). Strikingly, this ACC tumor also expressed multiple transcripts that
began in intron 1 directly upstream of exon 2 (Figure 3.1B, MYB TSS2, GenBank
X52126, Supplementary Figure S.3.1 & Supplementary Table S.3.1). These
transcripts are unlikely to be read-through from TSS1 since RNA splicing would
remove this intronic region. As controls, this assay detected TSS1 but not TSS2
transcripts in CD34+ hematopoietic progenitors and a salivary gland epidermoid
carcinoma cell line A253 (data not shown). Thus, we conclude these transcripts
in ACC T73 must originate from TSS2, as predicted from the sequencing data in
Figure 1A. Detailed investigation of TSS2 transcripts in T73 revealed replicate
transcripts from multiple potential transcription start sites that extended either
~180 nt or ~ 20 nt upstream of exon 2, into intron 1 (Figure 3.1B, +4409 nt and
+4569 nt respectively). Only the ~20 nt TSS2 transcript has been previously
described in the literature (Jacobs, Gorse, and Westin 1994). The ~180 nt TSS2
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transcript appears to be novel. In mammalian promoters transcription often
initiates at multiple, clustered start sites within a ~100 nt region (Carninci et al.
2006). Indeed, these data from an ACC tumor are consistent with multiple
transcription start sites upstream of exon 2, one of which has not been previously
described. (For the rest of this publication TSS1 and TSS2 will be used to refer to
the entire promoter regions, making no distinctions between individual
transcription start sites.)
Transcription initiating from TSS2 has been previously reported in
leukemia cell lines, where it accounted for a substantial proportion of total MYB
transcripts (Dassé et al. 2012; Jacobs, Gorse, and Westin 1994). However, TSS2
transcripts have not been described in human tumors or epithelial cells and only
one transcript has been annotated (GenBank Accession X52126). Here, we
provide the first evidence that TSS2 of the MYB gene is activated in an ACC
tumor. Which produced a mixture of MYB transcripts using two different
promoters, to express this important driver oncogene.
3.4.2 Myb transcription factors can activate cell-type specific MYB promoters
MYB TSS2 has been described previously (Dassé et al. 2012; Jacobs,
Gorse, and Westin 1994), still little is known about its regulation, function, or
significance in human tumors. Thus, we utilized reporter assays to perform basic
characterization of both MYB promoters. MYB TSS1 and TSS2 were cloned
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Figure 3.2 Cell type specific MYB promoters are activated by Myb
transcription factors.
(A) MYB promoter reporter constructs corresponding to TSS1 (blue) and TSS2
(red) are illustrated. Transcription start sites are designated +1 nt and indicated
with bent arrows. Predicted high quality (see methods) Myb binding sites are
indicated as open circles. (B) MYB promoters are activated differently in different
cell types. The reporters above were transiently transfected into three cell types
in the absence of exogenous activator. Fold activation is calculated relative
TSS1. (C) Both MYB promoters are activated by full-length and truncated Myb
proteins. Full-length Myb (MYB) and a truncated Myb protein predicted from ACC
tumors T349, which encodes
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upstream of the luciferase reporter gene (Figure 3.2A, Supplementary Figure
S.3.2), then introduced into different cell lines where their basal activities were
measured (Figure 3.2B). Both TSS1 and TSS2 functioned as bona fide
promoters in these assays, but they showed cell type-specific differences.
(Figure 3.2B) The two promoters displayed similar activities in A253 salivary
gland epidermoid carcinoma cells, but TSS2 was more active than TSS1 in
HEK293 human embryonic kidney cells, and the opposite was true in SW620
colorectal adenocarcinoma cells. In the ACC cell line MDACC-ACC-01(hTERT)
both reporters were active (data not shown). These data confirm that the region
upstream of exon 2 can act as a promoter in human cells and suggests that MYB
promoter selection is regulated in a cell-type specific manner.
Sequence motif analyses (Thomas-Chollier et al. 2011) revealed known
and novel transcription factor binding sites in each of the MYB promoters
(Supplementary Figure S.3.2). Within TSS1 there were predicted NF-κB binding
sites, a known activator of MYB expression in T-cells (Lauder, Castellanos, and
Weston 2001). While TSS2 had multiple binding sites for the Fox family of
transcription factors, including FOXO3, a transcription factor differentially
expressed (Brayer et al. 2016) and mutated (A. S. Ho et al. 2013) in ACC tumors.
These analyses also revealed multiple Myb binding site motifs in both promoter
regions (Figure 3.2A, open circles; Supplementary Figure S.3.2) suggesting they
could be auto-regulated by Myb proteins. Since gene expression changes elicited
by Myb transcription factors are responsible for driving tumorigenesis in over
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80% of ACC tumors (Frerich et al. 2018; Brayer et al. 2016) we investigated the
interaction of Myb transcription factors with its own promoters. HEK293TN cells
were transfected with each of the MYB promoter reporters along with
concurrently expressed Myb proteins. Figure 3.2C displays the fold activation of
the promoters by ectopically expressed Myb proteins relative to no Myb protein.
We found both MYB promoter regions were activated similarly (4 to 7-fold) by
full-length Myb and a Myb-Nfib fusion protein (T349, Figure 3.2C)(Brayer et al.
2016). The two MYB promoters were not significantly activated by a mutated Myb
transcription factor harboring a point mutation that disrupts DNA-binding activity
(Frampton et al. 1991)(data not shown). These data demonstrate that Myb
transcription factors are capable of activating of both TSS1 and TSS2 of the MYB
gene.
3.4.3 MYB TSS2 activation is widespread amongst, yet unique to ACC tumors
Once we established that a single ACC tumor used TSS2 and that this
promoter is active in reporter assays we asked if MYB TSS2 activation was a
common feature of all ACC tumors. To explore MYB TSS2 activation in all ACC
tumors we tabulated the RNA-seq reads that mapped to MYB exons in 55
previously sequenced FFPE ACC tumors (Frerich et al. 2018). Ovarian serous
cystadenocarcinoma (OVCA) exon count data from NCBI Genomic Data
Commons was used for comparison. Figure 3.3A illustrates MYB exon counts
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Figure 3.3. MYB TSS2 activation is unique to ACC tumors.
(A) Exon counts for the MYB gene (gene track below) were tabulated for ACC
(red, n=55) and ovarian cancer (OVCA, blue, n=55) RNA-seq data. ACC tumors
have a significantly lower use of exon 1, T-test *** p< 0.001 (B) ACC tumors have
higher TSS2 use than other tumors. TSS2 use in ACC tumors compared to other
tumor types. TSS2 use was calculated as a ratio of RNA-seq counts on exon 2
divided by those on exon 1 (exon2/exon1) for each tumor type. ACC RNA-seq
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data was previously published (7). RNA-seq data for remaining tumor types was
obtained from NCBI genomic data commons: Breast invasive carcinoma (BRCA),
Prostate adenocarcinoma (PRAD), Head and neck squamous cell carcinoma
(HNSC), Glioblastoma multiforme (GB), Acute Myeloid Leukemia (AML), Ovarian
serous cystadenocarcinoma (OVCA). Sample sizes were equalized to 55 tumors
in each dataset by random sampling. ACC tumors have a significantly different
ratio than the other tumors (ANOVA, *** p=0.001). The mean exon ratio for each
tumor type is tabulated below in parenthesis.
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(note the log scale) in ACC (red) and OVCA (blue) tumors for the first four exons
of the MYB gene (diagrammed below the dot plot). In OVCA tumors the first four
exons of MYB are transcribed at approximately equal levels, as would be
expected when transcription begins at TSS1. However, ACC tumors have
approximately 10-fold lower exon counts for exon 1 than exon 2, and a
significantly different average number of reads on exon 1 than OVCA tumors
(Figure 3.3A). In fact, in ACC tumors exon 1 was most often not transcribed at all,
approximately 60% (34 of the 55 total ACC tumors) had zero reads on exon 1.
We conclude that the disproportionately low use of exon 1 in ACC tumors is due
to TSS2 use described above, which is reflected in these RNA-seq data.
Next, we asked if the MYB TSS2 activation we observed in ACC tumors
also occurred in other tumor types. We compared our ACC RNA-seq data to the
following MYB expressing tumors from NCBI Genomic Data Commons: Breast
invasive carcinoma (BRCA), Prostate adenocarcinoma (PRAD), Head and neck
squamous cell carcinoma (HNSC), Glioblastoma mulitforme (GB), Ovarian
serous cystadenocarcinoma (OVCA), and Acute Myeloid Leukemia (AML). MYB
TSS2 use for each tumor type was quantified as the ratio of counts on exon 2
divided by those on exon 1 (exon2/exon1). An exon2/exon1 ratio close to 1 would
be expected from TSS1 use, where an equal number of reads were aligned to
exon 1 and exon 2. Conversely, a higher ratio indicates TSS2 use, due to exon 1
skipping and consequently more reads on exon 2. By this metric, TSS2 use was
highest in ACC tumors, the majority of which had very large exon2/exon1 ratios,
85

that averaged to 25.5 (Figure 3.3B, means tabulated in parenthesis below). In
contrast, all the other tumor types had dramatically lower average exon2/exon1
ratios, breast invasive carcinomas (BRCA) had the next highest at 8.4. Head and
neck tumors (HNSC = 4.2) had a mean exon2/exon1 ratio more than 6-fold lower
than the average of ACC tumors and 27-fold lower than the highest ACC tumor.
Interestingly, only 4 of the 55 total ACC tumors analyzed had an exon2/exon1
ratio below the average for the other head and neck tumors (HNSC=4.2, Figure
3B). Finally, ACC tumors had a significantly different exon2/exon1 ratio than the
other tumor types (ANOVA(F(6,155.61) =88.98, p<2.2e-16), with a significantly
larger exon2/exon1 ratio than each of the other tumor types individually (p < 2e16; Figure 3.3B). We conclude that MYB TSS2 use is widespread amongst ACC
tumors, but rarely used in other MYB-expressing tumors.
We utilized ACC tumor RNA-seq data to determine if the specific MYB
TSS2 activation we observed in ACC tumors could be due to chromosomal
translocations involving the MYB gene. Chromosomal translocations have been
implicated in activating expression of the MYB gene through recruitment of
distant enhancer elements to MYB TSS1, however, enhancer interaction with
TSS2 was not addressed (Drier et al. 2016). We compared the exon2/exon1 ratio
for ACC tumors with chromosomal translocations versus those without
translocation and found approximately half of the tumors that used TSS2 did not
have a chromosomal translocation, and there was no difference in the
exon2/exon1 ratio in these two classes of ACC tumors (Supplementary Figure
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S.3.3). While these data do not address whether NFIB enhancers can interact
with MYB TSS2, we conclude that enhancers recruited by chromosomal
translocations are not strictly responsible for activating MYB TSS2 in all ACC
tumors.
3.4.4 MYB TSS2 transcripts give rise to N-terminally truncated proteins
Thus far, we have described alternative transcriptional regulation of the
MYB gene in ACC tumors via activation of TSS2. This promoter was utilized by a
majority of ACC tumors but not other tumor types. In reporter assays TSS2 had
cell-type specific activity and could be activated by Myb proteins. We next
addressed the affects of TSS2 use on Myb proteins. Figure 3.4A illustrates the
mRNA isoforms encoded by TSS1 (top) and TSS2 (bottom) with the
corresponding amino acid sequence derived from each (middle). Translation of
full-length Myb begins at the first start codon located in exon 1 (M1) and together
exons 1 and 2 encode the first 47 amino acids (aa) of the full-length protein
(Figure 3.4A). However, when TSS2 is utilized (MYB TSS2 lower mRNA, Figure
4A), transcripts begin within intron 1 and do not include the usual start codon
(M1). Instead, translation is predicted to begin at the first in-frame start codon
(M21) located in exon 2, thereby skipping the first 20 aa of the Myb protein.
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Figure 3.4. MYB TSS2 mRNA encodes an N-terminally truncated Myb
protein isoform (∆N Myb).
(A) MYB transcripts beginning at TSS1 (top) include exons 1 and 2 which encode
amino acids 1-47 of the Myb protein (amino acid sequence below mRNA
transcript). MYB TSS2 transcripts begin at +4409 nt or +4569 nt downstream of
TSS1 (designed +1), skipping the entire first exon. These transcripts do not
include the first start codon (M1) and are instead predicted to begin translation at
residue M21, skipping the first 20 amino acids of the full-length Myb protein. (B)
The full-length Myb protein (amino acids 1-640) encodes conserved DNA-binding
and regulatory regions. TSS2 transcripts are predicted to encode a 20 amino
acid N-terminal deletion, producing the ∆N Myb isoform (amino acids 20-640).
The oncogenic AMV v-Myb (amino acids 72-442) also has a 72 aa N-terminal
truncation.
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The resulting proteins, illustrated in Figure 3.4B, have several highly conserved
domains comprising the DNA binding and regulatory regions of the protein. As
described above, Myb proteins translated from TSS2 are expected to have a 20
aa truncation to the amino terminus, producing the ΔN Myb protein isoform N Myb protein isoform
(Figure 3.4B, ΔN Myb protein isoform N Myb). Similarly, the oncogenic v-Myb protein harbors a 72 aa Nterminal truncation (Figure 3.4B, v-Myb). The skipped N-terminal residues are
highly conserved (Supplementary Figure S.3.4) and constitutively phosphorylated
by Casein kinase II at serine residues 11 and 12 (pS11, pS12) (Figure 3.4A &
3.4B, black lollipop)(Oelgeschlager et al. 1995; Cures et al. 2001; Luscher et al.
1990). The S11 phosphorylated site serves as the epitope for a popular Myb
antibody, which we exploited to illustrate full-length Myb and ΔN Myb protein isoform N Myb protein
isoform expression in western blot analyses (Supplementary Figure S.3.5).
Engineered Myb proteins expressed from cDNA vectors in HEK293TN cells were
submitted to Western blot analyses and probed with two Myb antibodies. An
antiserum directed towards the DNA-binding domain (PB84, Myb DBD, (Dash,
Orrico, and Ness 1996)), which is an essential domain present in all Myb
isoforms, detects both full-length and the ΔN Myb protein isoform N Myb isoform. In contrast, the
antibody directed towards the Myb pS11 residue (Myb pS11, ab45150) only
detects full-length Myb, not ΔN Myb protein isoform N Myb. (Unfortunately, similar experiments
performed on frozen ACC tumor samples were inconclusive due to extensive
Myb protein degradation/proteolysis, not shown.)
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The ΔN Myb protein isoform N Myb protein isoform has intact DNA-binding and regulatory
domains, and is predicted to be a functional transcription factor. Similarly, the
oncogenic v-Myb protein encoded by Avian Myeloblastosis Virus (AMV, Figure
3.4B) has an even larger 72 aa N-terminal truncation yet retains its DNA-binding
ability and is a functioning oncogenic transcription factor. We confirmed ΔN Myb protein isoform N Myb
was able to activate two known Myb regulated promoters (Frerich et al. 2018) in
reporter assays (Supplementary Figure S.3.6). Thus, the first 20 conserved
amino acids of c-Myb, including the phosphorylated residues, is not strictly
necessary for the DNA binding and transactivation ability of Myb transcription
factors (Oelgeschlager et al. 1995; 2001; Dini and Lipsick 1993). Still, the highly
conserved nature of this region suggests it serves an important regulatory
function, which is remains enigmatic. We predict that TSS2 transcripts produce
functionally active, N-terminally truncated Myb proteins and thus may represent
an additional mechanism by which ACC tumors abnormally activate MYB gene
expression.
3.4.5 ∆N Myb transcription factors have unique activity in cells
Using RNA-seq and 5’RLM-RACE we have described activation of MYB
TSS2 in ACC tumors, but the functional consequences of TSS2 use remained
unclear. We hypothesized that N-terminal truncation may alter the specificity of
Myb transcription factors in a manner that provided an oncogenic advantage to
ACC tumor cells. To test the first part of this hypothesis we performed RNA-seq
experiments on cells engineered to ectopically express either full-length Myb or
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∆N Myb transcription factors. Unfortunately, the ACC cell line (MDACC-ACC01(hTERT)) currently used expressed the related A-Myb transcription factor
which could have unknown influence on Myb stimulated gene expression, thus it
was not appropriate for these experiments. Instead, SW620 colorectal
adenocarcinoma cells were amenable to this experiment due to very little
endogenous Myb expression and both TSS1 and TSS2 were functional in our
transfection assays (Figure 3.2B). To perform these RNA-seq experiments we
infected cells with lentivirus particles that achieved up to ~95% transduction with
moderate over-expression of Myb proteins by Western blot analyses
(Supplementary Figure S.3.7). Note endogenous Myb protein expression in not
detected in empty vector treated cells. Protein and RNA were harvested from the
cells 48 hours after viral transduction and submitted for protein analyses and next
generation sequencing. Principal Components Analysis (PCA) of the gene
expression signatures elicited by ectopically expressed Myb transcription factors
showed clear separation of the three treatments (Figure 3.5A). Full-length Myb
(red) and ∆N Myb (cyan) were separated from empty vector control (EV, black)
along the first component (PC1, horizontal axis), which explained almost 70% of
the variation in the dataset. Even these initial analyses distinguished full-length
Myb (red) from ∆N Myb (cyan) along the second component (PC2, vertical axis),
which accounted for 18% of the variation in the dataset (Figure 3.5A). The PCA
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Figure 3.5. Myb and ∆N Myb transcription factors elicit both similar and
different gene expression changes in cells.
(A) Myb proteins were ectopically expressed in SW620 cells using lentiviral
particles. Total RNA was harvested at 48 hours post infection and prepared for
RNA-sequencing. PCA analyses distinguished empty vector control (black) from
full-length Myb (red) and ∆N Myb (cyan). (B) MYB isoforms regulated some
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overlapping but also many unique genes. Significantly diferentially expressed
genes (2-fold change, BH corrected P-value <0.05) were discovered for both Myb
isoforms versus empty vector control and displayed in the Venn diagram. (C) A
summary heatmap displays gene expression changes elicited by Myb
transcription factors. The sidebars above the heatmap indicate the following:
genes differentially expressed in Myb expressing ACC tumors versus Myb
negative ACC tumors (orange), genes discussed in the text (gray), genes
significantly differentially expressed in Myb versus ∆N Myb (cyan), and genes
differentially expressed by both Myb and ∆N Myb relative to empty vector control
(black). (D) ∆N Myb significantly differently activates or silences multiple genes.
Bar chart displays the log fold change relative to empty vector of the 80 genes
significantly differentially expressed between Myb (red) versus ∆N Myb (cyan).
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plot highlighted an exciting difference in the gene expression signatures elicited
by the two Myb protein isoforms.
We performed differential gene expression analysis, comparing each of
the Myb samples to empty vector control, and identified 409 genes that were upor down-regulated at least 2-fold by full-length Myb (adjusted p-val < 0.05; red,
Figure 3.5B), and 875 genes differentially regulated by ∆N Myb (cyan, Figure
3.5B). The total number of significantly differentially expressed genes discovered
for each comparison are displayed in parenthesis below the comparison label in
the Venn diagram (Figure 3.5B). Only a small proportion, ~35% (312/875 genes)
of ∆N Myb regulated genes, were also regulated by full-length Myb. In contrast,
∆N Myb caused an additional 563 (60% of the total) genes to be up- or downregulated at least 2-fold. Here it is apparent that full-length Myb and ∆N Myb
elicited genes expression changes in both overlapping and unique sets of genes
(Figure 3.5B). A summary heatmap of the gene expression analyses performed
above is included in Figure 3.5C (larger version Supplementary Figure S.3.8).
Genes commonly regulated by Myb and ∆N Myb are indicated by the black
sidebar along the left of the heatmap, whereas genes regulated significantly
differently between ∆N Myb and full-length Myb are indicated with cyan.
Additionally, genes discussed in this text are indicated in gray and genes
associated with Myb expression in ACC tumors (Frerich et al. 2018) are marked
with orange sidebars (Figure 3.5C). Some of the differentially expressed genes
are associated with important cell functions like cell cycle regulation (CDK3,
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COPS2, HSF4). While others have known oncogenic functions (MALAT1, GPC2,
LINC-PINT) or are associated with metastases in a variety of tumors (RAB40B,
PRSS3, NME1). Again it is apparent from the heatmap that full-length and ∆N
Myb regulated some genes similarly, but also regulated many genes differently.
Finally, we asked if ∆N Myb changed any single gene’s expression
significantly differently than full-length Myb. We performed differential gene
expression analyses with the same parameters used above but instead
compared ∆N Myb and full-length Myb directly. The differences in activity
between full-length and ∆N Myb are even more dramatic when these genes are
presented as a histogram, which plots the log fold change relative to empty
vector control both full-length Myb (red bars) and ∆N Myb (cyan bars, Figure
3.5D). Further investigation revealed that some genes are activated by both Myb
isoforms but are induced more dramatically by one Myb isform (e.g. at left; these
genes have both cyan and gray tick marks in the heatmap; Figure 3.5C),
whereas others are regulated in completely opposite directions by ∆N Myb and
full-length Myb proteins (e.g. center). For example, in comparison to empty
vector control the ESRP1 gene (genes are denoted with a black dots in Figure
3.5D) is significantly activated by Myb ~3.1 fold and ~6.4 fold by ΔN Myb protein isoform N Myb. Thus,
ΔN Myb protein isoform N Myb significantly activated ESRP1 ~2.0 fold more than full-length Myb, which
could be consistent with ΔN Myb protein isoform N Myb being an “unleashed” version of Myb. However,
this was not always the case, the NT5E gene was activated 195-fold by fulllength Myb but only 50-fold by ∆N Myb (Figure 3.5D). We also observed genes
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that were regulated by one isoform but not the other, like the oncogenic lincRNA
MALAT1, which is silenced by ΔN Myb protein isoform N Myb but is unchanged by full-length Myb.
Finally, full-length Myb and ΔN Myb protein isoform N Myb even regulated a few genes in a directly
opposing manner, for instance the ATP5F1D gene is silenced by full-length Myb
but activated by ΔN Myb protein isoform N Myb relative to empty vector (Figure 3.5D). These data
suggest that in some situations ΔN Myb protein isoform N Myb may have completely different
transcriptional activity and specificity than its full-length counterpart.
3.4.6 AN Myb uniquely modulates gene sets implicated in neuronal cell migration
The analyses above identified individual genes that were differentially
expressed between ΔN Myb protein isoform N Myb and full-length Myb. However, we questioned
whether ∆N Myb was able to coordinate the expression of multiple, functionally
related genes to elicit unique biological responses in cells. To address this the
significantly up and down regulated genes were submitted to gene set overrepresentation analyses using the ClusterProfiler R package to query the
Molecular Signatures Database (Yu et al. 2012; Subramanian et al. 2005). The
results are summarized in Figure 3.6A, where the left panel displays gene sets
discovered in ∆N Myb treated cells and the right panel displays gene sets
discovered in Myb treated cells. The color bar to the far right indicates gene sets
discovered in both Myb and ∆N Myb treated cells in gray, gene sets unique to ∆N
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Figure 6. ∆N Myb uniquely activates SEMA4D signaling, which is correlated
with ACC patient survival.
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(A) Gene set enrichment analyses were performed using the significantly
differentially expressed genes discovered in Figure 5. The top two gene sets
significantly enriched for each category plus selected gene sets unique to each
category are displayed. The color bar to the far right indicates the treatment in
which the gene set was enriched with enrichment in both Myb isoforms in gray,
enrichment in only full-length Myb in red, and enrichment in only ∆N Myb in cyan.
(B) Venn diagram of all the significantly enriched gene sets for each Myb isoform.
(C) Gene network for the REACTOME_SEMA4D_IN_SEMAPHORIN_
SIGNALING (R-HSA-400685) gene set. 25 of the 32 genes are displayed, gene
not included are: CD72, CDC42, LOC642076, MYL8P, MYL12A, PTPRC, RAC2,
RHOG, ROCKIP1. Fold change in ∆N Myb treated SW620 cells versus empty
vector control was used to color the gene nodes. (D) Unsupervised hierarchical
clustering using the 22 gene from the
REACTOME_SEMA4D_IN_SEMAPHORIN_SIGNALING gene set that were
expressed in ACC tumors. Two major groups were defined using the resulting
dendrogram, 21 tumors were in Group 1 (orange), and 34 tumors were in Group
2 (blue). The remainder of the ACC tumors clustered into multiple smaller groups
and are colored black. (E) There was a significant difference in ACC patient
survival when grouped based SEMA4D signaling. Tumors were assigned to
Group1, Group 2, or or excluded from these analyses based on the dedrogram in
panel D.
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Myb in cyan, and those unique to Myb in red (Figure 3.6A). (Full enrichment
results are provided in Supplementary Table S.3.3.) Approximately ~35% of the
discovered gene sets (165/423 sets) were enriched in both full-length Myb and
∆N Myb expressing cells (Figure 3.6B), this included many of the top-ranking
genes sets (categories denoted with gray in the side bar, Figure 3.6A). The
commonly regulated genes were significantly enriched in a previously published
ACC gene set from the DisGenNET database (Supplementary Figure S.3.9)
(Pinero et al. 2015). Further, full-length Myb and ∆N Myb both activated genes
which are over-represented in a previously published c-Myb target gene list
(LIU_CMYB_TARGETS_UP)(F. Liu et al. 2006), and silenced genes associated
with SEMA3B expression (KOYAMA_SEMA3B_TARGETS_UP, Figure 3.6A)
(Koyama et al. 2008). Thus, our enrichment results are consistent with previously
published findings and our own findings that ΔN Myb protein isoform N Myb and full-length Myb
commonly regulated some genes.
However, gene expression analyses also established that full-length Myb
and ∆N Myb transcription factors regulated many genes differently (Figure 3.5B).
Rather than taking the 80 significantly differentially expressed genes in isolation,
we rationalized that the cumulative affects of those genes regulated differently
plus those regulated in common could act in concert to affect widespread
changes in cells. Further, performing enrichment analyses in this manner would
be more representative of what happens in the cell. Thus, enrichment analyses
were performed as before, using all the significantly up and down regulated
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genes when compared to empty vector control for each Myb isoform. We found
that almost 70% of the enriched gene sets (239/423 sets) were unique to ∆N Myb
treated cells (Figure 3.6B). A selected subset of these unique gene sets are
included in Figure 6A (red and cyan side bar). Specifically, genes activated in
cells that expressed ∆N Myb were significantly enriched in SEMA4D associated
migratory cues (REACTOME_SEMA4D_INDUCED_CELL_MIGRATION_AND_
GROWTH_CONE_COLLAPSE and REACTOME_SEMA4D_IN_
SEMAPHORIN_SIGNALING (Garapati 2009b; 2009a))(Figure 3.6A). While
genes silenced in cells expressing ∆N Myb were significantly enriched in gene
sets associated with an immature or stem cell phenotype
(ZHANG_TLX_TARGETS_36HR_DN and BENPORATH_ES_1 (C. L. Zhang et
al. 2008; Ben-Porath et al. 2008)). Full-length Myb (categories indicated in red)
up-regulated genes enriched in RUNX1 gene sets
(TONKS_TARGETS_OF_RUNX1_RUNXT1_FUSION_HSC_UP (Tonks et al.
2007)) and silenced genes were enriched in p53 downstream targets
(PID_P53_DOWNSTREAM_PATHWAY (Schaefer et al. 2009))(Figure 3.6A).
We found the unique enrichment of SEMA4D signaling in ∆N Myb
expressing cells particularly interesting since it has long been associated with
neural cell migration and is implicated in a number of tumors (Capparuccia and
Tamagnone 2009). The annotated, validated REACTOME_SEMA4D_IN_
SEMAPHORIN_SIGNALING gene set, summarized more simply as SEMA4D
signaling hereafter, includes 32 genes, 6 of which were significantly differentially
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expressed in ∆N Myb treated SW620 cells. The SEMA4D signaling gene
interaction network is displayed in Figure 3.6C, the gene nodes are colored
according to the fold change in ∆N Myb treated SW620 cells versus empty vector
control cells. Evidence suggests that interactions between the Sema4D signaling
molecule and its receptor Plexin-B1 promoted perineural invasion via chemoattractive interactions in multiple tumors types (Binmadi et al. 2012). This same
pathway was studied in more mechanistic detail in breast carcinoma cells, where
SEMA4D signaling via its receptor Plexin-B1 either activated or suppressed cell
migration (Swiercz, Worzfeld, and Offermanns 2008). These contrasting effects
were linked to intermediate signaling molecules: signaling through ErbB-2
stimulated migration, whereas signaling through Met suppressed migration.
Indeed, in our RNA-seq experiments ∆N Myb up-regulated expression of the
SEMA4D, PLXNB1, and ERBB2 and down-regulated MET (Figure 3.6C). Thus,
the unique gene expression changes elicited by ∆N Myb in SW620 cells are
consistent with SEMA4D stimulated cell migration.
We conclude ∆N Myb and Myb transcription factors, which only differ by
20 N-terminal amino acids, regulate many of the same core genes, as would be
expected from the shared DNA-binding domain and C-terminal regulatory
domains. Yet the 20 aa N-terminal deletion also imparted unique transcriptional
activity, allowing ∆N Myb to activate and silence genes that full-length Myb did
not. Further, enrichment analyses suggest that ∆N Myb uniquely activated genes
involved in cell migration and perineural invasion.
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3.4.5 ∆N Myb geneset identified a poor outcome subgroup of ACC tumors
Due to ACC tumors known predilection for perineural invasion, and the
enriched gene sets potential involvement in this process, we performed
unsupervised hierarchical clustering of primary ACC tumors based on their
expression of SEMA4D signaling genes. The resulting dendrogram is displayed
in Figure 6D. ACC tumors sorted into distinct groups indicating the SEMA4D
signaling gene set captured meaningful biological variation in these tumors. The
majority of ACC tumors sorted into two large groups, with 21 tumors in Group 1
(orange) and 34 tumors in Group 2 (blue; Figure 3.6D). The remainder of the
ACC tumors sorted into many small groups (colored in black to the left side of the
dendrogram Figure 3.6D) and were quite variable in their gene expression of
SEMA4D signaling genes. Due to the small size of these groups (10 individuals
in 6 groups total) they were excluded from further analyses. We then performed
Kaplan-Meier analyses to evaluate the prognoses of the two main groups of ACC
tumors (Figure 3.6E). The median survival for all the ACC patients in this dataset
was 147 months with a 5-year survival rate of 72% (previously published (Frerich
et al. 2018)). When the ACC tumors were divided according to the dendrogram in
Figure 6D there was a significant difference in patient survival. Group 2 (blue)
was on par with the average survival for ACC patients, with a 5-year survival rate
above 80% (blue, Figure 3.6E). In contrast, Group 1 had significantly poorer
survival (log-rank p-value = 3.9x10-5), with a median survival of 61.7 months had
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significantly poorer survival and a much lower 5-year survival of ~55% (orange,
Figure 3.6E).
Thus, we have used RNA-seq to demonstrate ∆N Myb transcription
factors had significant unique activities in cells when compared to full-length Myb.
In these experiments ∆N Myb transcription factors uniquely elicited changes in
the SEMA4D signaling pathway, which are implicated in cell migration and
perineural invasion. Finally, the SEMA4D signaling pathway discovering in ∆N
Myb treated SW620 cells is significantly associated with differential survival of
ACC patients.
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3.5 DISCUSSION
Here we provide the first evidence that ACC tumors used an alternative
MYB promoter, which leads to expression of N-terminally truncated Myb proteins.
We demonstrated that MYB promoters have cell-type specific activity and MYB
TSS2 activation is widespread amongst but unique to ACC tumors, suggesting
that the underlying cause of TSS2 activation must be due to something specific
to ACC tumors. Chromosomal translocations are an important feature of ACC
tumors and have many established roles in activating the MYB gene, one of
which is to recruit enhancers downstream of the NFIB gene to interact with MYB
TSS1, stimulating its expression (Drier et al. 2016). It is probable that MYB TSS2
interacts with hijacked enhancers in ACC tumors that have chromosomal
translocations, although this remains to be tested. However, MYB TSS2
appeared to be activated in most (if not all) MYB expressing ACC tumors, even
those without detectable chromosomal translocations. Moreover, we found no
difference in TSS2 use between ACC tumors with translocations and those
without translocations, indicating that TSS2 is activated in ACC tumors
regardless of translocation status. Thus, MYB TSS2 activation may represent a
mechanism of MYB activation independent of chromosomal translocation.
Indeed, alternative promoter activation may explain how the MYB gene becomes
activated in ACC tumors without chromosomal translocations, a critical missing
link in ACC tumor biology.
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The implications of promoter selection extend far beyond transcriptional
regulation. Studies have shown alternative promoter use provides a mechanism
to modulate protein expression and activity, where for instance, N-terminally
truncated proteins produced from alternative promoters can have distinct
functional activities. We hypothesized that ΔN Myb protein isoform N Myb may have altered, even highly
oncogenic, activity in ACC tumors and thus used RNA-seq to investigate the
transcriptional activity of Myb and ΔN Myb protein isoform N Myb protein isoforms. We found that these
transcription factor isoforms, which have identical DNA-binding domains,
regulated hundreds of genes differently. Indicating ΔN Myb protein isoform N Myb had vastly different
activity in these cells, where it not only activated different primary targets but also
different downstream pathways altogether. This region is highly conserved,
indicating an important function. Early studies implicated N-terminal truncation in
oncogenesis, a mere 20 aa N-terminal truncation was sufficient to induce rapidonset tumors when expressed in chickens (Jiang et al. 1997). While,
phosphorylation of the S11 and S12 residues increased the specificity of fulllength Myb by destabilizing DNA-binding (Ramsay, Ishii, and Gonda 1991;
Oelgeschlager et al. 1995; 2001) this effect was easily overcome by protein-toprotein interactions with co-factors that anchored Myb to DNA (Oelgeschlager et
al. 1995). And it is clear N-terminally truncated Myb proteins are capable of
binding and activating transcription of target genes. Thus, the mechanism
responsible for the observed differences in Myb isoform activity is not clear.
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From our RNA-seq analyses a picture emerged potentially implicating ΔN Myb protein isoform N
Myb in ACC tumor migration and perineural invasion. In both Myb and ΔN Myb protein isoform N Myb
expressing cells the largely chemo-repulsive, anti-tumorigenic SEMA3B
associated migratory cues were down-regulated (Capparuccia and Tamagnone
2009). In addition, ΔN Myb protein isoform N Myb expressing cells alone displayed activated SEMA4D
chemo-attractive, pro-tumorigenic migratory cues. The combined influence of
these modulated pathways could have significant effect on the migratory
phenotype of tumor cells. Most ACC tumors express SEMA4D, and its receptor
PlexinB1 is up-regulated 5-fold in ACC tumors compared to normal salivary gland
(Brayer et al. 2016). We further found that classifying ACC tumors according to
SEMA4D signaling identified a significantly poorer outcome subgroup of tumors.
SEMA4D signaling has been implicated in the migration and invasiveness of a
variety of tumors. In epithelial cells SEMA4D triggered invasive growth (Giordano
et al. 2002) and stimulated migration in breast cancer cells in concert with ErbB-2
signaling (Swiercz, Worzfeld, and Offermanns 2008). Overexpression of the
SEMA4D receptor, PlexinB1, was correlated with invasiveness and metastasis in
prostate tumors (Wong et al. 2007). Finally, SEMA4D signaling is implicated in
perineural invasion, a hallmark of ACC tumors (Binmadi et al. 2012). Thus, our
results potentially link three disjointed aspects of ACC tumors; expression of a
previously unreported ΔN Myb protein isoform N Myb isoform activated SEMA4D signaling which is in
turn implicated in perineural invasion and patient outcome. The results described
herein could potentially be an important step towards improving treatment of this
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disease. In ACC tumors perineural invasion is linked to poor prognosis, local
recurrence, and significant patient morbidity. To date there are no specific
therapeutic intervention targeting perineural invasion in any tumor, and ΔN Myb protein isoform N Myb
may prove an attractive target in mitigating this aspect of the disease.
In total, we conclude that most ACC tumors utilized a rare alternative MYB
promoter. Myb proteins derived from this promoter are functional transcription
factors and are sure to contribute to ACC oncogenesis as such. Our RNA-seq
analyses revealed that ΔN Myb protein isoform N Myb can differently activate or silence hundreds of
genes, indicating N-terminal truncation via MYB TSS2 activation qualitatively
altered the specificity of Myb transcription factors. Further, ΔN Myb protein isoform N Myb alone was
able to silence anti-tumorigenic neuronal migratory signals while also stimulating
pro-tumorigenic neuronal migratory cues. Finally, expression of these same protumorigenic neuronal migratory cues in ACC tumors identified a significantly
poorer outcome subgroup of ACC tumors. These results potentially implicate ΔN Myb protein isoform N
Myb in stimulating perineural invasion in ACC tumors, the mechanisms of which
are still largely unknown (Bakst et al. 2019). It will be exciting to see future
studies that fully elucidate the role of TSS2 in MYB gene activation and
expression, the extent of its interaction with hijacked enhancers, and its full
functional consequences in ACC tumors.
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3.6 METHODS
3.2.1 Cell Culture and Luciferase assays
Human Kidney 293TN Producer cells (HEK239TN; Systems Biosystems)
and SW620 colorectal carcinoma cells (ATCC; CCL-227) were cultured in
Dulbecco's Modified Eagle's Medium (DMEM; ATCC) supplemented with 5% (v/v)
fetal bovine serum, 5% (v/v) newborn calf serum (Rocky Mountain Biologicals,
Inc.), and 1% Antibiotic-Antimycotic. A-253 epidermoid carcinoma cells (ATCC;
HTB-41) were cultured in McCoy’s 5A medium, supplemented with 5% (v/v) fetal
bovine serum, 5% (v/v) newborn calf serum, and 1% Antibiotic-Antimycotic. All
cells were cultured at 37 °C in 5% CO2. Media and supplements were purchased
from Life Technologies unless otherwise indicated.
For reporter assays, cells were seeded in 24 well plates with
approximately 4-6x104 cells per well. After 24 hours of growth, cells were
transiently co-transfected with 50 ng of luciferase reporter plasmid plus 50 ng of
activator plasmid (MYB cDNAs cloned into pcDNA3.0), or just reporter plasmid
without activator. Transfections were performed in duplicate using the TransIT2020 transfection reagent (Mirus) according to manufacturer instructions. Cells
were harvested, and firefly luciferase activity was measured after 48 hours using
the Luciferase Assay System (Promega). Background subtracted data was
normalized as stated in the Results. Reporter gene data are an average of three
independent biological replicates, with error bars representing the standard
deviation those.
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3.6.2 Tumor RNA-seq
ACC RNA-seq data processing and analysis was performed previously
(Frerich et al. 2018), data was downloaded from the NCBI BioProject database
using study accession number PRJNA287156. We obtained exon count data for
breast invasive carcinoma (BRCA), prostate adenocarcinoma (PRAD), head and
neck squamous cell carcinoma (HNSC), glioblastoma multiforme (GB), ovarian
serous adenocarcinoma (OVCA), and acute myeloid leukemia (AML) from NCBI
Genomic Data Commons. Analyses were limited to samples that reasonably
expressed MYB and had greater than 3 reads aligned to exon 2, this resulted in
55 ACC tumors in the final dataset. A random sampling of the NCBI Genomic
Data Commons datasets was used to equalize all datasets to 55 tumors total.
Exon counts were tabulated as the number of normalized RNA-seq reads that
mapped to each MYB exon in all tumor types, TSS2 use was then calculated as
the ratio of counts on exon 2 divided by those on exon 1 (exon2/exon1). RNAseq from two frozen in ACC tumors (T9 & T73) have been deposited in the NCBI
BioProject (accession PRJNA573669).
3.6.3 SW620 RNA-seq
SW620 cells were infected with concentrated lentiviral particles, so that
70-90% of cells were Green Fluorescent Protein (GFP) positive. RNA and total
protein were harvested 48 hours post transduction and submitted to Western
blotting and RNA-seq. RNA-seq experiments were performed as biological
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replicates. First, empty vector and Myb elicited gene expression was measured,
then a second experiment including empty vector, Myb, and ∆N Myb was
performed. Total RNA was extracted from cell pellets using the RNeasy Plus mini
kit (Qiagen). Ribosomal RNA was removed with the RiboGone kit (Clontech)
followed by cDNA synthesis using the SMARTer Universal Low Input RNA Kit for
Sequencing (Clontech). Libraries were prepared using the Ion Plus Fragment
Library Kit (Life Technologies) and sequenced using the Ion S5 systems (Life
Technologies) in the Analytical and Translational Genomics Shared Resource at
the University of New Mexico Comprehensive Cancer Center. Resulting RNA-seq
reads were aligned to the human genome (GRCh37; hg19) using TMAP (v5.2.25)
and gene counts were calculated using HT-Seq. Data were analyzed using R
v3.5.1 using the edgeR (v3.24.0), DESeq (v1.22.1), ggplot2 (v3.1.0), RUVSeq
(v1.16.0), limma (v3.38.2), mSIGDB (v6.1.1), survival (v3.6.1), stats (v3.6.1) and
clusterProfiler (v3.10.1) packages (Yu et al. 2012; Robinson, McCarthy, and
Smyth 2010; Anders and Huber 2010; Risso et al. 2014; Wickham 2019). RNAseq data is available for download from NCBI BioProject using accession number
PRJNA573669.
3.6.4 5’RLM-RACE
Total RNA was extracted from a frozen ACC tumors using the RNeasy
total RNA extraction kit (Qiagen) according to manufacturer specifications.
5’RLM-RACE was performed using the Generacer RLM RACE kit (Invitrogen)
according to manufacturer instructions. Briefly, total mRNA was
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dephosphorylated, decapped, then the Generacer oligo ligated to the 5’ends.
Reverse transcription was performed using either the provided oligo-dT primer or
a gene specific primer to exon 8. A nested PCR reaction was used to amplify
products (Supplementary Table S.3.1). A mixture of PCR products were TOPO
cloned (Invitrogen) and Sanger sequenced to verify insert sequence
(Supplementary Table S.3.1).
3.6.5 Protein and Western blots
Cell pellets were lysed in RIPA buffer with protease inhibitor for 10 min on
ice followed by sonication (Diagenode Bioruptor, high, 30 sec on/ 30 sec off, 5-10
min). Western blotting was performed using the WES automated system
(ProteinSimple), all results were verified via traditional blotting methods. Cell
lysates were diluted with sample 0.1x Sample Buffer (ProteinSimple) to a
concentration of ~0.6 ug/uL. Protein separation and quantification was performed
using the 12-230 kDa ladder according to manufacturer instructions. Antibodies
used were as follows: rabbit anti-Myb (Rabbit antisera PB84, directed against
amino acids 72-192 of Myb protein, 1:100, (Dash, Orrico, and Ness 1996)), rabbit
anti-Myb pS11 (ab45150; Abcam; 1:200), anti-βactin (1:100). Ready to use
mouse (042-205) and rabbit (042-206) HRP-conjugated secondary antibodies
were purchased from ProteinSimple. Myb antibodies were validated using Myb
protein expressed from plasmid cDNA (positive control) and paired untransfected
HEK293TN cell lysate (negative control) which do not express Myb.
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3.6.6 Cloning
All MYB expression vectors were cloned into pcDNA3.0 as previously
described (Brayer et al. 2016). Ectopically expressed Myb encoded the full-length
proteins, ∆N Myb has a 20 amino acid N-terminal truncation described in the text.
T349 is a C-terminally truncated Myb protein predicted from an ACC tumor, it
includes MYB exons 1-8 fused to NFIB exons 11-12 (Brayer et al. 2016). The
uc022bdo UCSC transcript was used as the NFIB reference, exons 11-12
encodes 73 amino acids. Reporter plasmids were cloned as follows: a 879 bp
fragment of MYB TSS1 was amplified from genomic DNA using MYB TSS1 FW
and RV primers (Supplementary Table S.3.1), and inserted into pGL3-basic with
NheI and HindIII restriction sites. A 779 bp fragment of MYB TSS2 was amplified
from genomic DNA using MYB TSS2 FW and RV primers (Supplementary Table
S.3.1) and inserted into pGL3-basic with NheI and XhoI restriction sites. Reporter
plasmid inserts were sequence verified via Sanger sequencing (Supplementary
Table S.3.1).
3.6.7 Promoter motif analyses
Transcription factor binding motifs were discovered using the transcription
factor affinity prediction (TRAP) set of web tools (Thomas-Chollier et al. 2011).
High quality motifs were defined as having a weight score above 2.5.
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CHAPTER 4: CONCLUSIONS, SIGNIFICANCE, FUTURE DIRECTIONS
4.1 How does MYB TSS2 become activated in ACC tumors?
As described in the third chapter ACC tumors have activated a rarely used
alternative MYB promoter. We found that the protein produced from this promoter
is truncated at the N-terminus (∆N Myb) and had unique functional effects in
cells. When the same pathways were investigated in ACC tumors we found a
significant difference in patient survival, indicating ∆N Myb contributes to ACC
tumor progression. However, it is still unknown how MYB TSS2 becomes
activated in these cells. MYB TSS2 was only activated in ACC tumors, not the
other tumor types studied, suggesting that the underlying cause of its activation
must be due to something unique to ACC tumors. We rejected our initial
hypothesis that distant enhancers hijacked by chromosomal translocations are
responsible for activating MYB TSS2 as it was not fully supported by these data.
Specifically, if hijacked enhancers were responsible only tumors with
chromosomal translocations would be expected to use MYB TSS2, instead many
ACC tumors that did not appear to harbor C-terminal defects still used MYB
TSS2. And tumors with and without chromosomal translocations had equally
elevated MYB TSS2 use.
Reporter assays demonstrated that MYB promoters are activated in a celltype specific manner (Figure 3.2), supporting the hypothesis that each cell type
expresses different specific transcription factors to activate MYB promoters to
different degrees. The MYB TSS1 promoter is extremely GC-rich, above 90% in
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some regions, whereas TSS2 is AT-rich. This is consistent with findings that
genes commonly have a primary GC-rich promoter and one or more GC-poor
alternative promoters and in embryonic stem cells GC-rich and GC-poor
promoters were regulated differently (Mikkelsen et al. 2007). This study also
found GC-rich promoters (like MYB TSS1) are active by default and must be
actively silenced. Whereas AT-rich alternative promoters (like MYB TSS2) are
inactive by default but can be selectively activated by cell-type specific
transcription factors. This is likely achieved through differential recruitment of the
basal transcriptional machinery to different core-promoter types by cell-type
specific factors (Northcott et al. 2014; Gross et al. 1998; Losick 1998). Specific
evidence for cell-type specific regulation of the MYB promoters was described in
normal myeloid cells and leukemia cells, where localization of the PBX2
transcription factor to TSS2 versus TSS1 had a role in which promoter was
activated (Dassé et al. 2012). Indeed, our reporter assays demonstrated that
MYB promoters are activated in a cell-type specific manner, most likely due to
differential expression of transcription factors (Figure 3.2). However, the activity
of our MYB promoter reporters did not reflect endogenous MYB promoter use in
the same cell. For instance, HEK293T and HCT116 cells both activated the MYB
TSS2 reporter much more than TSS1. Yet HEK293T cells do not express Myb
protein at all and HCT116 cells express the endogenous gene from MYB TSS1.
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Figure 4.1. Proposed model of MYB TSS2 activation in ACC tumors.
In most ACC tumors TSS2 is activated (larger bent arrow), but it remains
unknown how MYB TSS2 becomes activated. TSS1 and TSS2 are activated by
cell-type specific transcription factors (randomly colored spheres), and can be
activated by both truncated and full-length Myb proteins (red hexagon). However,
the identity of these transcription factors in ACC tumors is unknown. Expression
of the correct transcription factors alone is not enough to activate either
endogenous MYB promoter. Leading to my hypothesis that a combination of
permissive chromatin structure plus cell-type specific transcription factors is likely
required for TSS2 expression. However, ChIP-seq experiments show that the
canonical H3K4me3 active promoter mark (cyan) are present at the TSS1 but are
dramatically reduced at TSS2 (Drier et al. 2016), indicating this mark is probably
not responsible for activating TSS2. Thus, I propose that a different, unknown
histone mark is present at MYB TSS2 in ACC tumors, thus allowing its activation.
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These results indicated that expression of cell-type specific transcription factors
alone is not sufficient to activate either endogenous, chromatin embedded MYB
promoter. Thus, I hypothesis that MYB TSS2 is activated by unique interactions
between cell-type specific transcription factors, the general transcriptional
machinery, and permissive local chromatin structure (Figure 4.1).
Published ChIP-seq studies of the chromatin landscape in ACC tumors
revealed abundant H3K4me3 active promoter marks at MYB TSS1 but not at
MYB TSS2 (cyan peaks, Figure 4.1)(Drier et al. 2016). The H3K4me3 marks
primarily localized to the MYB TSS1 promoter region and the first intron. The
dramatic gap at MYB TSS1 is consistent with the hallmark nucleosome free
region at the transcription start sites, followed by high H3K4me3 levels
throughout the first half of the first intron. However, H3K4me3 levels drop
dramatically just before MYB TSS2 and there is no hallmark nucleosome free
region marking the transcripition start site. Which perhaps indicates the
H3K4me3 promoter mark is not responsible for providing the permissive
chromatin structure underlying TSS2 activation. These findings in ACC tumors
are consistent with findings in ES cells, where the primary GC-rich gene
promoter (like MYB TSS1) was marked with activating H3K4me3 and/or silencing
H3K27me3 but most AT-rich alternative promoters (like MYB TSS2) had neither
of these marks (Mikkelsen et al. 2007).
However, it remains unclear what specific transcription factors and histone
marks could be responsible for MYB TSS2 activation in ACC tumors. Defects in
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chromatin remodeling genes are noted in 35% of ACC tumors (A. S. Ho et al.
2013) and multiple genes significantly correlated with MYB TSS2 use in ACC
tumors are involved in histone modification and/or chromatin remodeling. For
example, the MORF4L2 (mortality factor 4 like 2) gene encodes a transcription
factor and a subunit of the NuA4 histone acetyltransferase multi-subunit complex
(Cai et al. 2003), which can acetylate H4K16, a mark associated with
transcriptional activation (R. Zhang, Erler, and Langowski 2017). Similarly, the
ATF2 (activating transcription factor 2) gene encodes a leucine zipper
transcription factor that can acetylate histones H2B and H4 in vitro (Bruhat et al.
2007). Finally, the H3K4me1 mark has been demonstrated to localize at an
active, intergenic alternative promoter in at least one situation (Skvortsova et al.
2016). Thus, I propose ChIP-seq to investigate if any (or all) of these histone
modifications have a role in activating MYB TSS2 in ACC tumors. Follow up
experiments with modified dCas9 could be utilized to directly modulate histone
marks at the endogenous MYB TSS2 in an non-MYB expressing cell line (like
HEK293T) to determine if the identified histone modifications are sufficient to
allow MYB TSS2 expression.
The recently described CRISPR affinity purification in situ of regulatory
elements (CAPTURE) protocol (X. Liu et al. 2017) would be an ideal method to
identify cell type specific transcription factors responsible for MYB TSS2
activation. The MYB TSS2 reporter is highly active in HEK293T cells, indicating
they have the required transcription factors and co-factors to drive its expression,
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and making them an ideal cell line to perform these assays. Specifically,
HEK293T cells would be engineered to express dCas9, the MYB TSS2 reporter
described in chapter 3, and a specific guide RNA directed toward the reporter.
We could then CAPTURE (X. Liu et al. 2017) the transcription factors and cofactors bound to the TSS2 reporter by immunoprecipitating dCas9 targeted to the
reporter plasmid sequence (a slight modification of the original protocol). Simple
Western blot analyses would detect CAPTURE of proteins identified as potential
MYB TSS2 activators in previous bioinformatic analyses (like ATF2, MORF4L2,
SNW1, MYB, FOXO3, PBX2, RNA polII positive control). If required this method
can also be paired with Mass Spec. analyses for high-throughput identification of
transcriptional complex composition.
4.2 N-terminal and C-terminal Myb truncations are cooperative
Although C-terminal truncations resulting from chromosomal
translocations were the first MYB defect observed in ACC tumors. Studies that
tracked ACC tumor progression surprisingly found that MYB-NFIB translocations
were not always an early event in ACC tumor formation (Costa et al. 2014).
Western blot analyses of Myb protein expression in ACC tumors showed that
tumors expected to express full-length c-Myb proteins had no detectable Myb
protein at all (Mitani et al. 2016). Interestingly, the antibody used to detect Myb in
this blot is unable to detect N-terminally truncated Myb proteins produced by
TSS2 transcripts (Supplementary Figure S.3.5). Further, it appeared from our
early RNA-seq analyses (Figure 2.1) that half of these ACC tumors expressed
119

full-length MYB transcripts and did not appear to harbor C-terminal truncations.
These findings are incompatible with well established MYB proto-oncogene
biology, ie the Myb protein must be truncated to unleash its oncogenic activity,
and the driver oncogene must be expressed early in tumor development. Thus,
the oncogenic driver in a quarter of ACC tumors is surely Myb, yet the Myb
isoform that appeared to be expressed is not oncogenic. At the time we
concluded that these ACC tumors must harbor cryptic genetic defects that
truncate the C-terminus, but are difficult to detect with RNA-seq. However, our
later discovery that ACC tumors used MYB TSS2, which leads to the expression
of N-terminally truncated Myb proteins provides an alternative explanation for all
these observations. RNA-seq analyses revealed that almost all ACC tumors used
TSS2, thus, those tumors that looked to express full-length MYB transcripts are
actually expected to harbor N-terminal truncations from MYB TSS2 use. Thus, I
hypothesize that N-terminal truncations via MYB TSS2 activation occur early to
initiate ACC tumor development, and chromosomal translocations occur later as
a second hit to the MYB gene. I predict that high-throughput CAP analysis of
gene expression (CAGE-seq) to map the 5’ends of all transcripts in ACC tumors
would confirm this hypothesis, and reveal further complexity in MYB gene
regulation.
However, if N-terminal truncation is sufficient to initiate and drive ACC
oncogenesis then why do chromosomal translocations occur? I hypothesize that
N-terminal plus C-terminal truncation creates a more oncogenic version of Myb
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compared to singly truncating either end. Thus, selection pressure would ensure
that tumor cells with double Myb truncations would be maintained. Indeed, the
prototypical oncogenic v-Myb protein is truncated at both termini (Figure 1.4).
Evidence suggests the N-terminus is involved in both modulating DNA-binding
affinity and protein-to-protein interactions with co-factors (Oelgeschlager et al.
2001; 1995; Ramsay, Ishii, and Gonda 1991; Burk and Klempnauer 1999). We
have provided evidence that N-terminally truncated Myb proteins have altered
transcriptional specificity. Extensive studies have shown that C-terminal
truncation releases Myb from self-inhibitory interactions (Dash, Orrico, and Ness
1996), participates in protein-to-protein interactions (Ness 2003), increases the
stability of the protein (Corradini et al. 2005; Kanei-Ishii 2004), and alters its
transcriptional specificity (Ness 2003; F. Liu et al. 2006). Further, high-throughput
gene expression analyses revealed that both N and C-terminal truncation had a
role in activating Myb proteins. Specifically, gene expression changes elicited by
full-length c-Myb, singly truncated Myb isoforms, and finally doubly truncated vMyb revealed each alteration additively converted the elicited gene expression
signature from c-Myb to v-Myb (F. Liu et al. 2006). Thus, historical evidence
supports my hypothesis that double truncation of Myb may be more oncogenic in
ACC tumors. Similar RNA-seq experiments to those performed in chapter 3
would be the first steps in testing this hypothesis in ACC tumors. N-terminal
truncation via MYB TSS2 activation may lead to slow-growing tumors with a
locally invasive phenotype but that do not metastasize to distant organs. Then
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further truncation of the C-terminus via chromosomal translocation results in
highly metastatic tumors with increased growth rate. Future studies will be
essential to fully determine the role and extent of N-terminal and C-terminal
truncation of Myb proteins in ACC tumors.
4.3 Why are truncated Myb transcription factors oncogenic?
Despite identification of the driver oncogene in the majority of ACC tumors
it remains unclear how Myb transcription factors initiate tumor development, drive
tumor progression, and metastatic disease. As a result there has been
frustratingly little progress towards controlling and eliminating this disease.
Discovery of both N-terminal and C-terminal truncations in ACC tumors is
consistent with extensive past studies that demonstrated Myb transcription
factors must be truncated to be oncogenic (Hu et al. 1991; Ramsay, Ishii, and
Gonda 1991; Lei et al. 2004; Fu and Lipsick 1996). Accumulating evidence
suggests that Myb truncation alters which genes it regulates, the transcription
factor code hypothesis summarized in the introduction (F. Liu et al. 2006; Ness
2003). Still it remains unclear what transcription factors and co-factors cooperate
with truncated Myb versus full-length Myb in ACC tumors and how those altered
interactions lead to tumor formation.
Gene expression studies of primary ACC tumors have produced a wealth
of information, but efforts to simplify, synthesize, and utilize these data have
proved challenging. ACC tumors express ~2,000 genes differently from normal
salivary gland (Brayer et al. 2016), and nearly the same number of genes were
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differentially expressed between Myb positive tumors and Myb negative ACC
tumors (Frerich et al. 2018). ChIP-seq experiments in ACC tumors revealed that
Myb proteins bound ~13,000 sites in the genome (Drier et al. 2016). Together
these studies make it apparent that Myb transcription factors completely
reprogram the gene expression signature of ACC tumors. So much so they
barely resemble their normal counterparts or other Myb negative ACC tumors.
Thus, it is becoming clear that Myb transcription factors are likely driving ACC
oncogenesis not by activating a single oncogene or pathway. Rather Myb
transcription factors completely reprogram normal cells by coordinating the
expression of hundreds (even thousands) of genes, which then modulate multiple
downstream pathways. The combined effects of this extensive reprogramming
results in oncogenic transformation. The major weakness of these highthroughput publications is that it remains unclear which of these thousands of
genes are important in activating which pathways, nor how they might interact to
drive oncogenesis. In essence, it is still completely unknown how truncated Myb
transcription factors are driving ACC tumor oncogenesis.
4.4 Myb in ACC tumor hallmarks: many unknowns
ACC tumors are typified by slow but indolent growth, late occurring
metastases, perineural invasion, dedifferentation, and increasing genome
instability with tumor progression (Figure 4.2)(Dillon et al. 2016; Dantas et al.
2015). As the driver oncogene, Myb is likely to directly contribute to some or all of
these characteristics, yet the mechanisms are not well understood. Uncontrolled
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proliferation is an essential hallmark of all tumors (Hanahan and Weinberg 2011).
ACC tumors specifically exhibit slow growth kinetics, which is likely the reason
chemotherapeutic agents are largely ineffective in these tumors (Dillon et al.
2016). Both NOTCH and Wnt signaling pathways have been implicated in driving
ACC tumor growth (Daa et al. 2004; Su et al. 2014). Myb is directly implicated in
coordinating Wnt signaling to control the timing and degree of cell proliferation
during normal salivary gland development (Matsumoto et al. 2016). Whether
truncated Myb similarly drives tumor cell proliferation by modulating Wnt
signaling has not been investigated in ACC tumors. NOTCH1 is mutated in a
subset of ACC tumors (Stephens et al. 2013; A. S. Ho et al. 2013), and in vitro
assays have implicated it in stimulating cell growth (Su et al. 2014; Panaccione et
al. 2016). As of yet no link between Myb and NOTCH signaling in driving ACC
tumor cell proliferation has been established. Thus it appears that ACC tumor cell
proliferation may be driven by both Myb dependent and Myb independent
pathways. Further studies are required to fully elucidate the interplay between
Myb, NOTCH, and Wnt signaling pathways and determine if these are the
predominant pathways driving ACC tumor proliferation.
ACC tumors exhibit several highly invasive characteristics: frequent local
recurrence, perineural invasion, and late occurring metastases (Jones et al.
1997; DeAngelis et al. 2011; Spiro 1997; Dantas et al. 2015; van der Wal et al.
2002). These characteristics are the main factors leading to patient morbidity and
mortality, hence they are a priority in improving patient treatment and outcome.
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Specifically, perineural invasion often results in partial facial paralysis from tumor
removal, local recurrence necessitates multiple invasive surgeries, and distant
metastases nearly always lead to death (Spiro 1997). Local recurrence,
perineural invasion, and metastases may be related manifestations of the same
activated pathways. Alternatively, they could be three distinct, unrelated tumor
characteristics. Again, what contribution the Myb oncogene has in driving these
characteristics has not been definitively established.

125

Figure 4.2. The role of truncated Myb in ACC tumor hallmarks.
ACC tumors are characterized by slow growth, multiple highly invasive
phenotypes, dedifferentiation, and increasing genome instability (outer teal
hexagons). As the oncogenic driver truncated Myb proteins (inner red hexagon)
likely have a role in many of these processes. However, only correlative links
have been made for some of these characteristics and many remain completely
unknown (indicated with ?). The identified pathways involved in each hallmark
are indicated in the outer tan hexagons, the main pathways involved in ACC
tumors hallmarks are NOTCH and Wnt signaling.
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Our studies directly implicate Myb transcription factors in stimulating
perineural invasion via the SEMA4D signaling pathway (Chapter 3). Several
previous studies have speculated that mutation and aberrant expression of
multiple neural associated genes is likely to have a role in perineural invasion
(Drier et al. 2016; A. S. Ho et al. 2013; Panaccione et al. 2016; Binmadi et al.
2012). Perineural invasion could indirectly contribute to local tumor recurrence
due to the difficulty of completely removing tumor cells that have invaded the
nerves (Dillon et al. 2016). One study found local recurrence almost always
occurred within the first 5 years of diagnosis (Mahrous 2010). Beyond this, the
mechanisms driving local recurrence of these tumors has not been investigated.
Distant metastases are the leading cause of treatment failure in ACC
patients, and average survival with metastatic disease as low as 19 months is
reported (Shingaki et al. 2014). ACC tumors most often metastasize to the lungs,
but have also been observed in the bone, liver, and brain (Shingaki et al. 2014;
Andreasen et al. 2018). While there are many more studies of ACC metastasis,
as a whole the mechanisms driving metastatic dissemination in ACC tumors are
unknown (Allen S. Ho et al. 2019). Chromosomal translocations involving MYB
are often maintained in distant metastases (Andreasen et al. 2018; Allen S. Ho et
al. 2019), indicating Myb expression is still required at the metastatic site. Myb
protein expression was also correlated with the expression of genes involved in
epithelial to mesenchymal transition (EMT) and increased lung metastases in
vivo mouse experiments (L.-H. Xu et al. 2019). Thus, multiple lines of evidence
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suggest Myb has a direct role in ACC tumor metastases. Similarly, Wnt signaling
has been implicated in ACC tumor EMT (C.-X. Zhou and Gao 2006) and
promoted cell invasion in vitro (R. Wang et al. 2015). Given the known
intersection of Myb and Wnt signaling and their similar effects in these studies, it
is likely that together they are a major pathway promoting distant metastases in
ACC tumors. Growing evidence has also implicated NOTCH signaling in ACC
tumor metastases, but as of yet a direct link to Myb has not been investigated.
NOTCH1 expression was elevated in metastases relative to matched primary
tumor (Su et al. 2014), and aberrant NOTCH signaling promoted EMT in vitro (Z.L. Zhao et al. 2015). A subset of ACC tumors harboring NOTCH mutations had a
significantly increased rate of metastasis (Ferrarotto et al. 2017), and metastases
had acquired significantly more mutations in the NOTCH1 gene relative to
primary tumors (Allen S. Ho et al. 2019). Thus, the same NOTCH and Wnt
signaling pathways implicated in ACC tumor proliferation are also implicated in
metastases and may represent both Myb independent and dependent pathways.
Interestingly, acquired NOTCH mutations in metastasis raises the question
whether Myb oncoproteins alone are able to initiate distant metastases, or if
more cooperating mutations are required? This is directly relevant to patient
treatment, early Myb driven metastases would respond well Myb therapeutic
intervention targeting Myb early in tumor development. Conversely, an
increasingly diverse rage of acquired mutations driving metastasis later in tumor
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progression would require personalized treatment for each patient, but could
occur later.
ACC tumor progression is often accompanied by dedifferentiation and
increased mutation burden, where low grade tumors have few genetic lesions but
high-grade tumors acquire many more genetic lesions (Costa et al. 2014; Su et
al. 2014). Further, highly transformed, dedifferentiated tumors are associated
with accelerated tumor progression and poor prognosis. Little is known regarding
the molecular mechanisms underlying dedifferentiation and genome instability.
Increasing genome instability is a characteristic of many tumors, including ACC
tumors which had an average of only 16 mutations in low grade tumors, but
advanced tumors had acquired up to 36 mutations (Allen S. Ho et al. 2019). ACC
tumors with activating NOTCH1 mutations were significantly more likely to have a
dedifferentiated phenotype (Ferrarotto et al. 2017), and NOTCH mutations are
often acquired as tumors progress (Allen S. Ho et al. 2019). Thus, increased
mutational burden, especially in the NOTCH pathway, due to genome instability
may lead to tumor progression and a dedifferentiated phenotype. In chapter 2 we
described a poor outcome subgroup of ACC patients whose gene expression
signature was linked to the differentiation state of the tumor (Frerich et al. 2018).
However, we did not observe association with Myb expression, NOTCH
mutations, nor activated NOTCH signaling. Which may indicate additional
unknown pathways are involved in this process. Nevertheless, dedifferentiation
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and genetic instability present a complex problem; likely making tumors more
aggressive, harder to target, and highly metastatic.
Studies have revealed many opportunities to develop targeted
therapeutics for ACC patients. It is clear that ACC tumors employ a multitude of
mechanisms to activate and ensure MYB oncogene expression, evidence of its
importance in disease maintenance. Future studies will be required to fully define
the mechanisms activating these oncogenes and how to disrupt them. To date
studies indicate that Wnt and NOTCH the primary pathways driving proliferation,
invasion, and metastases of ACC tumors, both attractive drug targets. Thus far it
appears that in ACC tumors these pathways operate in Myb dependent and Myb
independent manners. Importantly, these three pathways are interrelated and
dependent on each other in intestinal tumorigenesis (Germann et al. 2014), thus
further investigation to confirm the lack of interplay in ACC tumors is needed. Our
studies hint at a previously unappreciated diversity in ACC tumor transcriptomes,
indicating activation of pathways in addition to those already described that could
be harnessed to develop targeted therapies in the future.
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APPENDICES
Appendix A: Abbreviations
RNA-sequencing (RNA-seq)
breast invasive carcinoma (BRCA)
prostate adenocarcinoma (PRAD)
head and neck squamous cell carcinoma (HNSC)
glioblastoma multiforme (GB)
ovarian serous cystadenocarcinoma (OVCA)
acute myeloid leukemia (AML)
RNA-ligase mediated rapid amplification of cDNA ends (5’RLM-RACE)
amino acid (aa)
MYB gene promoter (TSS1)
MYB gene alternative promoter (TSS2)
Avian Myeloblastosis Virus (AMV)
DNA binding domain (DBD)
transactivation domain (TAD)
full-length Myb (FL Myb)
N-terminally truncated Myb (ΔN Myb protein isoform N Myb)
Integrative Genome Browser (IGV)
formaldehyde-fixed paraffin-embedded (FFPE)
untranslated region (UTR)
Principal components analyses (PCA)
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empty vector (EV)
differentially expressed (DE)
Adenoid cystic carcinoma (ACC)
Formalin-fixed, paraffin-embedded (FFPE)
Ribonucleic acid sequencing (RNA-seq)
Fluorescence In Situ Hybridization (FISH)
Chromatin immunoprecipitation (ChIP)
CRISPR affinity purification in situ of regulatory elements (CAPTURE)
CAP analysis of gene expression sequencing (CAGE-seq)
epithelial to mesenchymal transition (EMT)
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Appendix B: Chapter 2 supplementary tables and figures
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Supplementary Figure S.2.1. Large version of Figure 2.2C
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Supplementary Figure S.2.2. Large version of Figure 2.4E
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Appendix C: Chapter 3 supplementary tables and figures
Supplementary Table S.3.1. PCR primers and Sanger sequencing. PCR
primers used for 5’RLM-RACE amplification of MYB transcripts are listed. 5’RLMRACE products were TOPO clones and screened with TSS1 and TSS2 specific
primers. Multiple colonies predicted to be TSS1 and TSS2 were Sanger
sequenced, good quality sequences are included here. MYB promoter regions
were cloned into the pGL3-basic reporter vector as described in the methods.
Inserts were Sanger sequenced and included here.
name

MYB TSS1
FW
MYB TSS1
RV
MYB TSS2
FW
MYB TSS2
RV

sequence
cloning primers
gaggaggagGCTAGCTTGCCGCCCACTTGTATTGA
gaggaggagaagcttGGGGTCTTCGGGCtATGG
gaggaggagGCTAGCGACTCTGACTAACAAGTGGCCT
gaggaggagctcgagCTCATCATCCTCGTCACTGCT
5’RLM RACE primers

RACE
MYBex8 RV
RACE
MYBex6RV
RACE
MYBex6 FW
RACE
MYBex7 RV
RACE
MYBex7/8 FW

MYB TSS1
RACE

TGGTAGCACCTGCTGTCCTTTTAGC
TGTTCGACCTTCCGACGCATTGTAG
CCACTGGAATTCTACAATGCGTCGGA
CAGCTGGCTGAGGGACATTGACTAT
GCCGCAGCCATTCAGAGACACTAT
5’RLM RACE Sanger sequencing
CTCTTTCTCCTGAGAAACTTCGCCCCAGCGGTGCGGAGCGCCGCTGCGCAG
CCGGGGAGGGACGCAGGCAGGCGGCGGGCAGCGGGAGGCGGCAGCCCG
GTGCGGTCCCCGCGGCTCTCGGCGGAGCCCCGCGCCCGCCGCGCCATGG
CCCGAAGACCCCGGCACAGCATATATAGCAGTGACGAGGATGATGAGGACTT
TGAGATGTGTGACCATGACTATGATGGGCTGCTTCCCAAGTCTGGAAAGCGT
CACTTGGGGAAAACAAGGTGGACCCGGGAAGAGGATGAAAAACTGAAGAAG
CTGGTGGAACAGAATGGAACAGATGACTGGAAAGTTATTGCCAATTATCTCCC
GAATCGAACAGATGTGCAGTGCCAGCACCGATGGCAGAAAGTACTAAACCCT
GAGCTCATCAAGGGTCCTTGGACCAAAGAAGAAGATCAGAGAGTGATAGAGC
TTGTACAGAAATACGGTCCGAAACGTTGGTCTGTTATTGCCAAGCACTTAAAG
GGGAGAATTGGAAAACAATGTAGGGAGAGGTGGCATAACCACTTGAATCCAG
AAGTTAAGAAAACCTCCTGGACAGAAGAGGAAGACAGAATTATTTACCAGGC
ACACAAGAGACTGGGGAACAGATGGGCAGAAATCGCAAAGCTACTGCCTGG
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MYB TSS2
+4409 nt
RACE

MYB TSS2
+4405 nt
RACE
MYB TSS2
+4569 nt
RACE

MYB TSS2
+4566 nt
RACE

ACG
AACCAGTTTACAATACTAGAGCAACAGAATGCAGCAAACAATCTTGTTGTGCA
AGTTTTCAAAGTTTTGTCTTCATAACCTTTGAAAAGATTGTTGAGGAGTTTTGT
GTAAGTTTTGTAATCCAGTAGTAGTCTAAATCCTCTTGTTTCAGCCCACGTCTA
CCCATTCTTATTTCTGCAGCATATATAGCAGTGACGAGGATGATGAGGACTTT
GAGATGTGTGACCATGACTATGATGGGCTGCTTCCCAAGTCTGGAAAGCGTC
ACTTGGGGAAAACAAGGTGGACCCGGGAAGAGGATGAAAAACTGAAGAAGC
TGGTGGAACAGAATGGAACAGATGACTGGAAAGTTATTGCCAATTATCTCCCG
AATCGAACAGATGTGCAGTGCCAGCACCGATGGCAGAAAGTACTAAACCCTG
AGCTCATCAAGGGTCCTTGGACCAAAGAAGAAGATCAGAGAGTGATAGAGCT
TGTACAGAAATACGGTCCGAAACGTTGGTCTGTTATTGCCAAGCACTTAAAGG
GGAGAATTGGAAAACAATGTAGGGAGAGGTGGCATAACCACTTGAATCCAGA
AGTTAAGAAAACCTCCTGGACAGAAGAGGAAGACAGAATTATTTACCAGGCA
CACAAGAGACTGGGGAACAGATGGGCAGAAATCGCAAAGCTACTGCCTGGA
CG
AGTTTACAATACTAGAGCAACAGAATGCAGCAAACAATCTTGTTGTGCAAGTT
TTCAAAGTTTTGTCTTCATAACCTTTGAAAAGATTGTTGAGGAGTTTTGTGTAA
GTTTTGTAATCCAGTAGTAGTCTAAATCCTCTTGTTTCAGCCCACGTCTACCCA
TTCTTATTTCTGCAGCATATATAGCAGTGACGAGGATGATGAGGACTTTGAGAT
GTGTGACCATGACTATGATGGGCTGCTTCCCAAGTCTGGAAAGCGTCACTTG
GGGAAAACAAGGTGGACCCGGGAAGAGGATGAAAAACTGAAGAAGCTGGTG
GAACAGAATGGAACAGATGACTGGAAAGTTATTGCCAATTATCTCCCGAATCG
AACAGATGTGCAGTGCCAGCACCGATGGCAGAAAGTACTAAACCCTGAGCTC
ATCAAGGGTCCTTGGACCAAAGAAGAAGATCAGAGAGTGATAGAGCTTGTAC
AGAAATACGGTCCGAAACGTTGGTCTGTTATTGCCAAGCACTTAAAGGGGAG
AATTGGAAAACAATGTAGGGAGAGGTGGCATAACCACTTGAATCCAGAAGTTA
AGAAAACCTCCTGGACAGAAGAGGAAGACAGAATTATTTACCAGGCACACAA
GAGACTGGGGAACAGATGGGCAGAAATCGCAAAGCTACTGCCTGGACG
ACCCATTCTTATTTCTGCAGCATATATAGCAGTGACGAGGATGATGAGGACTTT
GAGATGTGTGACCATGACTATGATGGGCTGCTTCCCAAGTCTGGAAAGCGTC
ACTTGGGGAAAACAAGGTGGACCCGGGAAGAGGATGAAAAACTGAAGAAGC
TGGTGGAACAGAATGGAACAGATGACTGGAAAGTTATTGCCAATTATCTCCCG
AATCGAACAGATGTGCAGTGCCAGCACCGATGGCAGAAAGTACTAAACCCTG
AGCTCATCAAGGGTCCTTGGACCAAAGAAGAAGATCAGAGAGTGATAGAGCT
TGTACAGAAATACGGTCCGAAACGTTGGTCTGTTATTGCCAAGCACTTAAAGG
GGAGAATTGGAAAACAATGTAGGGAGAGGTGGCATAACCACTTGAATCCAGA
AGTTAAGAAAACCTCCTGGACAGAAGAGGAAGACAGAATTATTTACCAGGCA
CACAAGAGACTGGGGAACAGATGGGCAGAAATCGCAAAGCTACTGCCTGGA
CG
ATTCTTATTTCTGCAGCATATATAGCAGTGACGAGGATGATGAGGACTTTGAGA
TGTGTGACCATGACTATGATGGGCTGCTTCCCAAGTCTGGAAAGCGTCACTT
GGGGAAAACAAGGTGGACCCGGGAAGAGGATGAAAAACTGAAGAAGCTGGT
GGAACAGAATGGAACAGATGACTGGAAAGTTATTGCCAATTATCTCCCGAATC
GAACAGATGTGCAGTGCCAGCACCGATGGCAGAAAGTACTAAACCCTGAGCT
CATCAAGGGTCCTTGGACCAAAGAAGAAGATCAGAGAGTGATAGAGCTTGTA
CAGAAATACGGTCCGAAACGTTGGTCTGTTATTGCCAAGCACTTAAAGGGGA
GAATTGGAAAACAATGTAGGGAGAGGTGGCATAACCACTTGAATCCAGAAGT
TAAGAAAACCTCCTGGACAGAAGAGGAAGACAGAATTATTTACCAGGCACAC
AAGAGACTGGGGAACAGATGGGCAGAAATCGCAAAGCTACTGCCTGGACG
Reporter sequences for MYB promoters

137

MYB TSS1Luc.

MYB TSS2Luc

TTGCCGCCCACTTGTATTGAAGCGTCCTTTGTCACTAACAAGTTAAATTAGAG
ATGTTATTTATTTAAGAAGAAGGAAAAAAAACCCTAGCCAAACAGCCTATGAAT
ACATATGCTCACATCCCCTACTCCTCCAACTCCTAATTTCCCCGTCTCCAGAG
GGCACAGTTGTAAACCTTGACGAAAATCCAATCTTCTGTGCGGGAATTTCCC
CCCACCGCTTGCCGCCCCCGCGACAGTGAGTGGGAGCTGGAGGAGCTCTG
GTCCCGCTGCCCGGGAGCACGCGGAGCCGGGCGACCGCGGTGCGGCAGC
CAGGGAGGAGGGGAGGCGGCGGGACTGGGCGCGGGTCGGCGCCGCCGC
GACCCGGGAGCGGGGTTTGCTCAGGAAAAGGCGCCGTCGCGGCCCCCGG
CCACCCCTCCCTGGCCCCGGGCTCCCTGCCCGCGCGCCTCCCGGGCCTCG
CGGCGCGCTAGGCGCACCGCGGCGGCGCGAGCGCCGAATGGGAGCGGCG
ACCCGGCCAGCCCGGCAGCCCCGCGGGCGGCAGCCAGGGCGACCGCGGA
GGCGGCGGGCAGGGCGCGTGCGCACTGCAGGGGCGCCAGATTTGGCGGG
AGGGGGAGTGTCCAAAGCTCTTTGTTTGATGGCATCTCTGTTTACAGAGTTTA
CACTTTAATATCAACCTGTTTCCTCCTCCTCCTTCTCCTCCTCCTCCGTGACC
TCCTCCTCCTCTTTCTCCTGAGAAACTTCGCCCCAGCGGTGCGGAGCGCCG
CTGCGCAGCCGGGGAGGGACGCAGGCAGGCGGCGGGCAGCGGGAGGCG
GCAGCCCGGTGCGGTCCCCGCGGCTCTCGGCGGAGCCCCGCGCCCGCCG
CGCtATGGCCCGAAGACCCC
GACTCTGACTAACAAGTGGCCTAATTATTCACTTAGTTACTCTAGAAACTAAGT
ATTGTAAACATGGGCACAAGTTGGATCAACCAGGCCTGGAGTTGTGAGCAAT
TTGGTATTAATTTTATTTACAAAACATTAAAGCTTGATCACTCAATGTTCTTATCT
TTGCTTTGGTTTTAAAATCCTTTCCTCTTAGATTCTCCTAATCCTCTAGACTTTA
TGGGATCACTATAATTCTGTTTTGCGCTGTACTACTTCTTGATTTTTTTCTTCTT
TTAATAAAACAAAAACCCCATTGGAATAGCATAGTTGAATTGTTTATTATGTTTG
AGAAATATTATTTAAACGATGTGACAGATGCCAAAGATTTTGAGTGTGCACTTA
TATAAAGGACATGGGTTCTTGTTCCTTTTCTTATCCTTAACCTTAAGTTTTCAAC
TTAAACCTTCACTGGTTGGAAGGTGGCCAAATGTGTAACTTGTCCCTGGTCTA
ATAGTAACAGCAGGTTCAGACATGCAGGGGAATAGGAAGGTGCCAGGTCCTT
GGCCGTGTCTGTGGATACCCATAACAGCAGAACCAGTTTACAATACTAGAGCA
ACAGAATGCAGCAAACAATCTTGTTGTGCAAGTTTTCAAAGTTTTGTCTTCATA
ACCTTTGAAAAGATTGTTGAGGAGTTTTGTGTAAGTTTTGTAATCCAGTAGTAG
TCTAAATCCTCTTGTTTCAGCCCACGTCTACCCATTCTTATTTCTGCAGCATAT
ATAGCAGTGACGAGGATGATGAG
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Supplementary Figure S.3.1. Details of 5’ RLM-RACE MYB TSS2 products.
MYB TSS2 5’RLM-RACE products were TOPO cloned and several colonies were
submitted for Sanger sequencing. Importantly, 5’RLM-RACE, as performed here,
is not quantitative and does not have single base resolution. Upon sequencing
we found transcripts that extended 180 nt, 176 nt, 20 nt and 17 nt upstream of
exon 2. We have grouped these into ~180 nt and ~20 nt groups in the main
figure. Three colonies from each of the two groups were sequenced.
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Supplementary Figure S.3.2. Predicted transcription factor binding sites for
the MYB promoter reporters. Portions of both MYB gene promoters were
clones upstream of the luciferase reporter. Transcription factor binding motifs
were discovered using the transcription factor affinity prediction (TRAP) set of
web tools (Thomas-Chollier et al. 2011). High quality motifs were defined as
having a weight score above 2.5. Binding sites for Myb were discovered in both
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sequences (bold underlined). Additional binding sites were discovered
(underlined).
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Supplementary Figure S.3.3. Exon ratio for ACC tumors with and without
chromosomal translocation. ACC tumors were classified as full-length MYB
expression, truncated MYB, or unknown by visual inspection of RNA-seq reads
across the MYB gene. Chromosomal translocations almost always result in
expression of a truncated gene; thus truncation is used as a substitute for
translocation. Conversely, full-length MYB expression is derived from an
unbroken gene, which has not been translocated. The ratio of reads on
exon2/exon1 was plotted for full-length and truncated Myb expressing samples,
unknown samples were not included. There was not a significant difference in
exon ratio, and TSS use, between tumors with truncated and full-length MYB
gene expression.
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Supplementary Figure S.3.4. N-terminal conservation of the Myb protein.
An alignment of the first 240 amino acids of the human Myb protein with the
chicken, mouse, AMV v-Myb, and ∆N Myb protein sequence. The N-terminus is
highly conserved, as is the DBD.
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Supplementary Figure S.3.5. ∆N Myb is not detected by a common Myb
antibody. Myb proteins were over-expressed in HEK293TN cells and lysates
were probed with two anti-Myb antibodies. Rabbit serum that detects the DNA
binding domain detects both full-length and ∆N Myb isoforms. Whereas, the
popular anti-Myb pS11 antibody (ab45150) is unable to detect ∆N Myb isoforms.

Supplementary Figure S.3.6. ∆N Myb proteins have similar activities to fulllength Myb in reporter assays. Two previously described (Frerich et al. 2018)
Myb-responsive reporter genes were used. A portion of the engrailed gene (EN1)
promoter and the SOX4 gene promoter were cloned upstream of the firefly
luciferase reporter gene. Their response to ∆N Myb and full-length Myb were
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assayed in HEK293TN cells. ∆N Myb binds and activates expression in a
reporter assay and is thus a functional transcription factor.
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Supplementary Figure S.3.7. Western blot of ectopically expressed Myb
isoforms. SW620 cells were transduced with lentiviral particles to express empty
vector, full-length Myb or ∆N Myb. Protein and RNA (used for RNA-seq) were
harvested at 48hrs. Western blot analyses were performed using rabbit serum
that detects the DNA-binding domain of Myb proteins, and actin was probed as a
loading control. Full-length Myb and ∆N Myb were expressed in relatively equal
quantities.
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Supplementary Figure 8. Large heatmap of SW620 RNA-seq. A summary
heatmap displays gene expression changes elicited by Myb transcription factors.
Tick marks above the heatmap indicate the following: genes differentially
expressed in Myb expression ACC tumors versus Myb negative ACC tumors
(orange), genes discussed in the text (gray), genes differentially expressed in
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Myb versus ∆N Myb (cyan), and genes differentially expressed by both Myb and
∆N Myb (black).
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Supplementary Figure S.3.9. Myb transcription factors elicited a gene
signature significantly enriched in an ACC disease set. Genes regulated in
common by full-length Myb and ∆N Myb were submitted to DisGenNET (Pinero
et al. 2015) using the clusterProfiler R package (Yu et al. 2012). The significantly
enriched disease sets, including ACC, are displayed.
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